WO2009116491A1 - ヒトインターフェロンαサブタイプα8及びその変異蛋白質を特異的に認識するモノクローナル抗体 - Google Patents
ヒトインターフェロンαサブタイプα8及びその変異蛋白質を特異的に認識するモノクローナル抗体 Download PDFInfo
- Publication number
- WO2009116491A1 WO2009116491A1 PCT/JP2009/055039 JP2009055039W WO2009116491A1 WO 2009116491 A1 WO2009116491 A1 WO 2009116491A1 JP 2009055039 W JP2009055039 W JP 2009055039W WO 2009116491 A1 WO2009116491 A1 WO 2009116491A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ifnα8
- monoclonal antibody
- human
- antibody
- mutant protein
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/249—Interferons
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6866—Interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
- G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
- G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
- G01N2030/8831—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials involving peptides or proteins
Definitions
- the present invention relates to a novel monoclonal antibody against human interferon ⁇ (hereinafter, interferon may be abbreviated as “IFN”), and specifically, human IFN ⁇ subtype ⁇ 8 (hereinafter referred to as human IFN ⁇ subtype ⁇ 8).
- IFN ⁇ 8 human IFN ⁇ subtype ⁇ 8
- monoclonal antibody specific for the mutant protein a novel monoclonal antibody against human interferon ⁇
- IFN ⁇ subtype ⁇ 8 human IFN ⁇ subtype ⁇ 8
- monoclonal antibody specific for the mutant protein a novel monoclonal antibody against human interferon ⁇
- IFN was discovered as a virus growth inhibitory factor produced by cells infected with the virus.
- IFN three types of ⁇ / ⁇ , ⁇ , and ⁇ with different receptors are known for IFN, and at least 13 types of subtypes are known for human IFN ⁇ .
- Human IFN ⁇ is a recombinant preparation produced in E. coli, a natural preparation induced by stimulating peripheral blood leukocytes or cultured lymphoblastoid cells with Sendai virus (HVJ), etc. It is widely applied clinically as a therapeutic agent for malignant neoplasms and hepatitis B and C.
- IFN has been studied for its immunoregulatory action, allergic diseases, autoimmune diseases such as diabetes, and the involvement of diseases caused by viral infection, and is interested in the dynamics in vivo.
- a bioassay based on antiviral activity using cultured cells is used for measuring the activity of IFN.
- the bioassay best reflects the physiological activity of IFN, it is known that it takes time to measure and is susceptible to factors that affect the physiological function of cells used in the assay.
- a natural IFN containing a plurality of types and subtypes is produced (for example, Yanai Y.), “Journal of Interferon and Cytokine Research ( Journal of Interferon & Cytokine Research), Vol. 21, No. 10, pp. 835 to 841 (2001)), and directly measuring the activity of each of these subtypes and analyzing their functions was extremely difficult.
- IFN ⁇ 4 human IFN ⁇ subtype ⁇ 4
- kits that can specifically quantify human IFN ⁇ using mouse-derived monoclonal antibodies are also available (for example, sold by JIMRO Corporation, trade name) Although it is a “human IFN- ⁇ measurement kit”), the IFN ⁇ subtype cannot be specifically identified.
- IFN ⁇ 8a IFN ⁇ 8a
- IFN ⁇ 8b IFN ⁇ 8b
- IFN ⁇ 8c IFN ⁇ 8c
- human IFN ⁇ may act as a co-agonist (enhancement agent) of other subtypes (Japanese Patent Publication No. 9-509955), and IFN ⁇ 8 mutant proteins having different specific activities (International Publication No. WO 2006/051805 pamphlet), researching the physiological functions of these human IFN ⁇ subtypes and mutant proteins, and developing them as pharmaceutical preparations, When examining blood kinetics and comparing them, an assay system that allows specific, accurate, and sensitive quantification of the protein mass without being affected by other physiological factors as in bioassays Is needed.
- Monoclonal antibodies can recognize specific antigenic determinants (epitope), but there are differences in their specificity and affinity, so they are suitable for constructing an IFN ⁇ 8-specific and highly sensitive assay system. There is a need to develop monoclonal antibodies. Further, in order to use IFN ⁇ 8 or a mutant protein thereof for pharmaceutical purposes, it is necessary to purify the IFN ⁇ 8 or the mutant protein specifically and in large quantities. It is necessary to develop a monoclonal antibody suitable for the preparation of an antibody column in which nonspecific adsorption of other proteins is small and IFN ⁇ 8 or its mutant protein can be easily eluted from an antibody column prepared using the monoclonal antibody .
- the first object of the present invention is to provide a monoclonal antibody specific to IFN ⁇ 8 and its mutant protein.
- the second object of the present invention is to provide a hybridoma capable of producing such a monoclonal antibody.
- the third object of the present invention is to provide a method for detecting IFN ⁇ 8 and its mutant protein using such a monoclonal antibody.
- the present invention provides various viral diseases, autoimmune diseases, diabetes, psoriasis, rheumatoid arthritis, multiple sclerosis, Behcet's disease, aplastic anemia, nephritis, systemic lupus erythematosus, comprising such a monoclonal antibody as an active ingredient.
- Another object is to provide a therapeutic agent for immunodeficiencies including acquired.
- the present inventors have intensively studied a novel monoclonal antibody that specifically recognizes IFN ⁇ 8 and its mutant protein, and have completed the present invention.
- the gist of the present invention is to provide a novel monoclonal antibody that specifically recognizes IFN ⁇ 8 and its mutant protein.
- a method for specifically detecting IFN ⁇ 8 and its mutant protein is provided.
- a method for specifically purifying IFN ⁇ 8 and its mutant protein from a test sample containing impurities is provided.
- therapeutic agents for various diseases such as allergies, immunodeficiencies or autoimmune diseases, which involve IFN ⁇ 8.
- the monoclonal antibody of the present invention specifically binds to IFN ⁇ 8 and its mutant protein, and does not substantially bind to other IFN types and subtypes. Therefore, since the monoclonal antibody of the present invention exhibits an immune reaction only with IFN ⁇ 8 and its mutant protein in the test sample, IFN ⁇ 8 and its mutant protein in the test sample are specifically, qualitatively or quantitatively detected. Has the advantage of being able to. Further, it has an advantage that IFN ⁇ 8 and its mutant protein can be collected with high purity and efficiency from a mixture containing IFN ⁇ 8 and its mutant protein and a contaminant.
- FIG. 3 is an explanatory diagram showing an example of a calibration curve of rIFN ⁇ 8 obtained by an enzyme immunoassay by a sandwich method using the monoclonal antibody ⁇ 8 # 139 mAb of the present invention as a solid phase antibody and ⁇ 8Y36-2 mAb as a labeled antibody.
- the IFN ⁇ 8 referred to in the present invention refers to a known polypeptide having the amino acid sequence of IFN ⁇ 8 described in, for example, International Publication No. WO 2006/051805 pamphlet, and the amino terminus (hereinafter referred to as “N terminus”) is cysteine. It refers to three types of polypeptides having an amino acid sequence composed of 165 or 166 amino acids.
- the polypeptides may be referred to as IFN ⁇ 8a, IFN ⁇ 8b, and IFN ⁇ 8c (see, for example, International Publication No. WO 2006/051805 pamphlet), and in this specification, these may be collectively referred to as IFN ⁇ 8. Regardless of the origin and origin of the polypeptide, it may be natural, recombinant, or chemically synthesized.
- the mutated protein of IFN ⁇ 8 in the present invention refers to a polypeptide in which one or two or more amino acids constituting a polypeptide having the amino acid sequence of IFN ⁇ 8 are substituted with other amino acids, and at least described below, Hybridoma mAb-IFN ⁇ 8 # 139 (National Institute of Advanced Industrial Science and Technology, Patent Biological Depositary Center, Deposit Number FERM BP-11081, hereinafter abbreviated as “ ⁇ 8 # 139”) and mAb-IFN ⁇ 8Y36-2 (Independent Administrative Industrial Technology)
- ⁇ 8 # 139 National Institute of Advanced Industrial Science and Technology, Patent Biological Depositary Center, Deposit Number FERM BP-11081, hereinafter abbreviated as “ ⁇ 8 # 139”
- mAb-IFN ⁇ 8Y36-2 Independent Administrative Industrial Technology
- the 145th arginine residue from the N-terminal of the amino acid sequence of IFN ⁇ 8 disclosed by the present applicant in International Publication No. WO 2006/051805 is converted to a leucine residue, isoleucine residue or valine residue.
- the monoclonal antibody referred to in the present invention includes all monoclonal antibodies specific to the above-mentioned IFN ⁇ 8 and its mutant proteins, and the origin / origin, class, isotype, etc. are not limited.
- the monoclonal antibody of the present invention can be obtained by using IFN ⁇ 8 or a mutant protein thereof or an antigenic fragment thereof as an antigen. Specifically, for example, a hybridoma of an antibody-producing cell collected from a mammal immunized with such an antigen and a cell derived from a mammal capable of infinite growth is prepared, and the monoclonal antibody of the present invention is produced from this. Can be obtained by selecting clones of hybridomas capable of producing, and culturing them in vitro and in vivo.
- IFN ⁇ 8 that can be an antigen and its mutant protein
- IFN ⁇ 8 induced by adding a virus such as HVJ to lymphoblastoid cells such as BALL-1 cells.
- IFN ⁇ 8 prepared by gene recombination technique or chemical synthesis method or a mutant protein thereof may be used.
- BALL- One cell-derived IFN ⁇ 8 may be prepared, and IFN ⁇ 8 or a mutant protein thereof may be prepared by the method described in International Publication No.
- WO 2006/051805 pamphlet They are usually used in a completely purified or partially purified state. In order to obtain an antigenic fragment, these completely purified products or partially purified products are chemically or enzymatically degraded, or the amino acid sequence of IFN ⁇ 8a, IFN ⁇ 8b or IFN ⁇ 8c disclosed in International Publication No. WO 2006/051805 pamphlet is used. Based on this, the desired peptide may be synthesized.
- Immunization may be performed by a conventional method.
- the above-mentioned IFN ⁇ 8, a mutant protein thereof or a fragment thereof may be administered alone or together with an appropriate adjuvant into mammals intravenously, intradermally, subcutaneously or intraperitoneally, and kept for a certain period of time.
- the mammal is not particularly limited, and the type, size, and sex are not limited as long as the desired antibody-producing cells can be obtained.
- rodents such as rats, mice, hamsters and the like are used, and the optimal one is selected in consideration of compatibility with cells derived from mammals capable of infinite growth described later.
- the inoculation amount of the antigen is usually about 5 to 500 ⁇ g / animal and divided into 2 to 5 times at intervals of about 1 to 2 weeks. Inoculate. Then, 3 to 5 days after the final inoculation, the spleen is removed and dispersed to obtain spleen cells as antibody-producing cells.
- the antibody-producing cells thus obtained are fused with cells derived from mammals capable of infinite growth to obtain fused cells containing the target hybridoma.
- Mammals derived from mammals capable of infinite growth usually include P3-NS1-Ag4-1 cells (ATCC TIB18), P3-X63-Ag8 cells (ATCC TIB9) and SP2 / O-Ag14 cells (ATCC CRL1581), Y3Ag1 .2 (ATCC CRL1631) and other mouse and rat myeloma-derived cell lines, or mutants thereof are used.
- fusion accelerators such as polyethylene glycol and Sendai virus, and methods using electric pulses are used.
- cell fusion is derived from mammals capable of infinite growth with antibody-producing cells in a fusion medium containing a fusion accelerator.
- the cells are suspended at a ratio of about 1: 1 to 1:10, and incubated in this state at about 30 to 40 ° C. for about 1 to 5 minutes.
- a general common medium such as MEM medium, RPMI 1640 medium and Iskov modified Dulbecco medium may be used, and it is desirable to remove serum such as bovine serum.
- the fused cells obtained as described above are transferred to a selection medium such as HAT medium, and cultured at about 30 to 40 ° C. for about 3 days to 3 weeks to obtain cells other than the hybridoma. To kill.
- the hybridoma is cultured by a conventional method, and the reactivity of the antibody secreted into the culture with IFN ⁇ 8 and its mutant protein is tested.
- conventional methods for detecting antibodies such as enzyme immunoassay, radioimmunoassay and bioassay are used. For example, Koji Toyama and Minami Ando "Monoclonal Antibody Experiment Manual" published by Kodansha Scientific Co., Ltd.
- a hybridoma producing an antibody specific for IFN ⁇ 8 and its mutant protein is immediately cloned by a limiting dilution method or the like to obtain a single-cloned hybridoma according to the present invention.
- the monoclonal antibody of the present invention can be obtained by culturing such a hybridoma in vitro or in vivo.
- a conventional method for culturing cells derived from mammals is used.
- the culture is transplanted to a warm-blooded animal other than a human.
- monoclonal antibodies are collected from the ascites and / or blood.
- ⁇ 8 # 139 Independent Administrative Agency, National Institute of Advanced Industrial Science and Technology, Patent Biological Depositary, Accession Number FERM BP-11081
- ⁇ 8Y36-2 Independent Administrative Institution, National Institute of Advanced Industrial Science and Technology, Patent Biological Depositary, Accession No.
- the monoclonal anti-IFN ⁇ 8 antibody produced by (2) has a low non-specific reaction when these antibodies are used for detection of IFN ⁇ 8 and its mutant protein, and can detect a small amount of IFN ⁇ 8 specifically and with high sensitivity. .
- these hybridomas are characterized by high production ability of monoclonal antibodies and easy culture in vivo and in vitro. To collect monoclonal antibodies from culture, ascites or blood, conventional methods in the art for purifying antibodies in general are used.
- Individual methods include, for example, salting out, dialysis, filtration, concentration, centrifugation, fractional precipitation, gel filtration chromatography, ion exchange chromatography, affinity chromatography, high performance liquid chromatography, gel electrophoresis and isoelectric focusing. Electrophoresis etc. are mentioned, These are applied in combination as needed.
- the purified monoclonal antibody is then concentrated and dried to be liquid or solid depending on the application.
- the monoclonal antibody of the present invention is, for example, a DNA encoding a heavy chain and light chain variable region containing the nucleotide sequence represented by SEQ ID NO: 3 or 4 and 5 in the sequence listing, or SEQ ID NO: 12 or 13, DNAs encoding the heavy chain and light chain variable regions having the base sequence shown by 14, respectively, and known DNAs encoding heavy chain and light chain constant regions (see, for example, JP-A-2007-252372), respectively.
- a ligated gene is synthesized by PCR or chemical synthesis, and is transformed into a known expression vector (pcDNA3.1 (available from Invitrogen)) that enables expression of the gene by a conventional method to prepare a transformant.
- pcDNA3.1 available from Invitrogen
- These antibodies are produced by expressing them in a host such as Chinese high-star ovary cells (CHO cells) or E. coli. From the nutrient solution can be obtained by purifying the antibody using Protein A column or the like.
- the antibodies produced by these methods may be used as they are for the purpose described later. As long as they have the ability to bind to IFN ⁇ 8 and its mutant proteins, Fv, scFv, Fab containing the antigen recognition site of the antibody. , F (ab ′), Fab ′ and the like can be advantageously used.
- the monoclonal antibody of the present invention has a wide range of uses in various fields that require detection of IFN ⁇ 8 and / or its mutant protein. That is, when a labeled immunoassay such as a radioimmunoassay, an enzyme immunoassay, or a fluorescent immunoassay is applied to the monoclonal antibody of the present invention, qualitative or quantitative analysis of IFN ⁇ 8 and / or its mutant protein in a test sample specifically, quickly and accurately. can do. In such analysis, the monoclonal antibody of the present invention is used after being labeled with, for example, a radioactive substance, an enzyme and / or a fluorescent substance.
- a labeled immunoassay such as a radioimmunoassay, an enzyme immunoassay, or a fluorescent immunoassay
- a labeled immunoassay is characterized by being able to analyze a large number of test samples at one time, requiring less time and labor for analysis, and being highly accurate in analysis compared to a bioassay. Therefore, the detection method according to the present invention is extremely useful for process control, quality control of products when producing IFN ⁇ 8 and / or its mutant protein, and clinical diagnosis of diseases involving IFN ⁇ 8.
- the present invention does not relate to the labeling of the monoclonal antibody or the labeling assay itself, and therefore will not be described in detail.
- P. Thyssen translated by Eiji Ishikawa, “Enzyme Immunoassay”, published in 1989 by Tokyo Chemical Dojin, Various methods are described in detail on pages 196 to 348.
- these monoclonal antibodies can be used as a solid phase antibody and / or a labeled antibody in the enzyme antibody method to obtain IFN ⁇ 8 and its antibody. Mutant proteins can be specifically detected.
- the protein is 50 to 2,000 pg / ml. It is possible to construct a highly sensitive assay system that can be detected within a range of 1 and that substantially does not detect other human IFN ⁇ subtypes other than IFN ⁇ 8.
- monoclonal antibodies suitable for the highly sensitive enzyme antibody method by the sandwich method include, for example, ⁇ 8 # 139 (Independent Administrative Agency, National Institute of Advanced Industrial Science and Technology, Patent Organism Depositary, Accession No.
- FERM BP-11081 A monoclonal antibody produced by a hybridoma of ⁇ 8Y36-2 (Incorporated Administrative Agency, National Institute of Advanced Industrial Science and Technology, Patent Organism Depositary, Accession No. FERM BP-11082) can be exemplified.
- these two types of monoclonal antibodies are used as a solid phase antibody and a labeled antibody, human IFN ⁇ subtypes other than IFN ⁇ 8 are not detected even at a concentration of 2,000 pg / ml, and non-specific Since almost no reaction due to adsorption is observed, IFN ⁇ 8 and its mutant protein can be measured with high sensitivity and accuracy.
- the monoclonal antibody of the present invention is also extremely useful for purification of IFN ⁇ 8 and its mutant protein by immunoaffinity chromatography.
- a purification method comprises contacting the monoclonal antibody of the present invention with a mixture of the IFN ⁇ 8 and its mutant protein and a contaminant such as a contaminant protein other than the protein to adsorb only the protein to the monoclonal antibody;
- the method comprises a step of desorbing the adsorbed protein from the monoclonal antibody, and both steps are usually performed in an aqueous medium.
- the monoclonal antibody of the present invention is usually used in a state of being bound to a gel-like water-insoluble carrier, and the water-insoluble carrier is packed into a cylindrical tube or the like in a column shape, and for example, the lymphoblastoid cell line BALL is used.
- the culture supernatant containing IFN ⁇ produced by stimulating -1 with HVJ the culture medium of a transformant capable of producing IFN ⁇ 8 or its mutant protein, or a partially purified product thereof is passed through, substantially only the protein Adsorbs to the monoclonal antibody on the water-insoluble carrier.
- the adsorbed protein can be easily desorbed by changing the hydrogen ion concentration around the monoclonal antibody.
- the pH is on the acidic side, usually pH 2 to 3
- a monoclonal antibody belonging to the IgM class when used, it can be eluted at an alkaline pH, usually pH 10-11.
- a monoclonal antibody suitable for this purpose for example, monoclonal antibodies produced by ⁇ 8 # 139 and ⁇ 8Y36-2 can be exemplified.
- the monoclonal antibody of the present invention is expressed in CHO cells or E. coli using the above-described recombinant techniques, etc. to prepare chimeric antibodies, humanized antibodies or human antibodies.
- IFN ⁇ 8 develops by preparing fragments such as Fv, short chain antibody (scFv), Fab, F (ab ′), Fab ′ fragment, diabodies and minibodies having the antigen recognition site of Various viral diseases, allergies, atopic diseases, autoimmune diseases, diabetes, psoriasis, rheumatoid arthritis, multiple sclerosis, Behcet's disease, aplastic anemia, nephritis, systemic lupus erythematosus and It can also be advantageously used as an active ingredient of a therapeutic agent for various diseases such as immunodeficiencies including acquired diseases.
- An antibody produced by ⁇ 8 # 139 that can be produced is desirable.
- An antibody produced by hybridoma ⁇ 8 # S56-1 described later can also be advantageously used because it can neutralize IFN ⁇ 8 activity.
- the preparation of the monoclonal antibody alone can be used, but usually, a form of preparation containing one or more pharmaceutically acceptable additives is desirable and used for the treatment of the disease. It is optional to further blend other active ingredients.
- the daily dose of the monoclonal antibody of the present invention is 0.001 mg to 2,000 mg, preferably 0.01 to 1,000 mg, more preferably 0.1 mg to 1,000 mg per day for an adult. Or it may be divided into multiple doses.
- the monoclonal antibody of the present invention which is preferable as an immunoassay, IFN ⁇ 8 or its mutant protein purification, or a therapeutic agent for diseases associated with the onset or exacerbation of IFN ⁇ 8, will be described more specifically.
- a monoclonal antibody capable of achieving the intended object of the present invention If so, antibodies produced by hybridomas of ⁇ 8 # 139 and ⁇ 8Y36-2 are desirable, regardless of their origin or amino acid sequence.
- the heavy chain variable region contains one or more of the amino acid sequences shown in SEQ ID NOs: 21 to 23 in the sequence listing, and / or the light chain variable region contains amino acids shown in SEQ ID NOs: 24 to 26.
- an antibody comprising one or more of the sequences, or a heavy chain variable region comprising one or more of the amino acid sequences represented by SEQ ID NOs: 27 to 29 in the sequence listing, and / or a light chain variable region comprising SEQ ID NOs: 30 to 32
- An antibody comprising one or more amino acid sequences represented by Furthermore, the heavy chain variable region includes all amino acid sequences represented by SEQ ID NOs: 21 to 23 in the sequence listing, and the light chain variable region includes all amino acid sequences represented by SEQ ID NOs: 24 to 26, or heavy antibodies. More preferred is an antibody comprising all the amino acid sequences represented by SEQ ID NOs: 27 to 29 in the chain variable region and all the amino acid sequences represented by SEQ ID NOs: 30 to 32 in the light chain variable region.
- an antibody comprising the amino acid sequence represented by SEQ ID NO: 9 or 10 in the sequence listing, and comprising the amino acid sequence represented by SEQ ID NO: 11 in the sequence listing in the light chain variable region, or SEQ ID NO: 18 in the sequence listing in the heavy chain variable region Further preferred is an antibody comprising the amino acid sequence represented by 19 and comprising the amino acid sequence represented by SEQ ID NO: 20 in the sequence listing in the light chain variable region.
- an antibody comprising an amino acid sequence represented by SEQ ID NO: 9 or 10 in the heavy chain variable region and an amino acid sequence represented by SEQ ID NO: 11 in the light chain variable region has neutralizing activity against IFN ⁇ 8. It is desirable because it has a high correlation with activity.
- These antibodies can be used as they are, by using their partial sequences, or by preparing recombinants by deleting, adding, or substituting about 1 to 100 of these amino acids.
- Human IFN ⁇ 8 and its mutations Quantitative and qualitative analysis of IFN ⁇ 8 that specifically recognizes protein, IFN ⁇ 8 purification, and further, chimeric antibody, humanized antibody, or human antibody suitable for each use such as disease treatment involving IFN ⁇ 8, clinical diagnosis, Preparation by a known method (for example, JP 2004-533217 A or JP 2007-252372 A) can also be advantageously carried out.
- amino acid deletions, additions and substitutions are preferably in the range of several, preferably 1 to 5, more preferably 1 to 3, and particularly preferably 1 or 2. Such deletions and addition substitutions may be introduced into hypervariable sites that define the specificity of the antibody, but other sites are usually desirable.
- the recombinant human IFN ⁇ subtype and the IFN ⁇ 8 mutant protein containing IFN ⁇ 8 (hereinafter, the recombinant type may be abbreviated as “r”) used in the following examples are both Hayashibara Corporation. Using materials prepared with E. coli at the Institute of Biochemistry (Yanai Y., etc.), “Journal of Interferon & Cytokine Research”, Volume 21, Volume 10 No., pages 835 to 841 (2001) and international publication WO 2006/051805). As rIFN ⁇ 8, a peptide having the amino acid sequence of IFN ⁇ 8b was used (see International Publication No.
- WO 2006/051805 pamphlet human IFN ⁇ subtype ⁇ 2b (hereinafter abbreviated as “IFN ⁇ 2”), nIFN ⁇ 8, mouse IFN ⁇ / ⁇ and rat IFN ⁇ of natural type (hereinafter, the natural type may be abbreviated as “n”) are: “Journal of Interferon & Cytokine Research”, Vol. 21, No. 10, using materials prepared by Hayashibara Biochemical Research Institute, Inc. (Yanai Y.) 835-841 (2001)).
- Human IFN ⁇ (hereinafter human IFN ⁇ is abbreviated as “IFN ⁇ ”) and consensus IFN (hereinafter sometimes referred to as “Con IFN”) are products sold by Mochida Pharmaceutical Co., Ltd. and Astellas Pharma Inc., respectively. Were purchased and used.
- Human IFN ⁇ (hereinafter, human IFN ⁇ is abbreviated as “IFN ⁇ ”) and human tumor necrosis factor (human TNF ⁇ , hereinafter, human TNF ⁇ is abbreviated as “TNF ⁇ ”) are purchased from Cosmo Bio Corporation. did.
- IFNs and cytokines used in the following examples are summarized in Table 5 described later.
- the subtypes ⁇ 1, ⁇ 5, ⁇ 6, and ⁇ 10 of human IFN ⁇ are abbreviated as IFN ⁇ 1, IFN ⁇ 5, IFN ⁇ 6, and IFN ⁇ 10, respectively.
- IFN ⁇ 1, IFN ⁇ 5, IFN ⁇ 6, and IFN ⁇ 10 are abbreviated as IFN ⁇ 1, IFN ⁇ 5, IFN ⁇ 6, and IFN ⁇ 10, respectively.
- IFN ⁇ 8-MUT2 the 145th arginine residue from the N-terminal cysteine residue of the amino acid sequence of IFN ⁇ 8b consisting of 166 amino acid residues, the 146th alanine residue as the serine residue and the 149th as the 149th
- IFN ⁇ 8-MUT2 A mutant protein of IFN ⁇ 8 in which the methionine residue is replaced with a tyrosine residue, and the 145th arginine residue from the N-terminal cysteine residue of the amino acid sequence of IFN ⁇ 8b are leucine.
- IFN ⁇ 8-MUT3 A mutated protein of IFN ⁇ 8 (hereinafter abbreviated as “IFN ⁇ 8-MUT3”) in which the 146th alanine residue was substituted with a serine residue and the 149th methionine residue was substituted with a tyrosine residue was used.
- rIFN ⁇ 8 derived from E. coli, protein concentration 510 ⁇ g / ml, 1.27 ⁇ 10 8 IU / ml
- the titer of IFN (international unit: IU) was measured by a bioassay using as an index the inhibitory effect on cytopathic effect of Sindbis virus on FL cells.
- Intravenous injection 10 ⁇ g of antigen containing no adjuvant was intravenously administered as the final immunization 3 days before cell fusion
- the spleen cells and the parent mouse SP2 / O-Ag14 cells were cultured in serum-free RPMI 1640 medium (pH 7.2), which had been prewarmed to 37 ° C., with a cell density of 2.5 ⁇ 10 5 cells. / Ml and 5 ⁇ 10 4 cells / ml, and after centrifugation, the precipitate was collected.
- 1 ml of serum-free RPMI 1640 medium (pH 7.2) containing 50% (w / v) polyethylene glycol having an average molecular weight of 1,500 daltons was added dropwise to this precipitate over 1 minute, followed by incubation at 37 ° C. for 1 minute.
- hybridoma culture supernatant The culture supernatant of each well in which the hybridoma has grown (hereinafter referred to as “hybridoma culture supernatant”) is collected and subjected to an enzyme immunoassay by the direct method described below to produce a hybridoma that produces an antibody reactive to rIFN ⁇ 8. Selected. Subsequently, this hybridoma was repeatedly applied with limiting dilution according to a conventional method, and clones of hybridomas ⁇ 8 # 44, ⁇ 8 # 59, ⁇ 8 # 98, ⁇ 8 # 139 that stably produce monoclonal antibodies showing affinity for rIFN ⁇ 8, ⁇ 8 # 145 was obtained.
- hybridoma ⁇ 8 # 139 that is, mAb-IFN ⁇ 8 # 139, on February 15, 2008, 1-1-1 Higashi 1-chome, Tsukuba-shi, Ibaraki, Japan National Institute of Advanced Industrial Science and Technology Deposited with the Patent Organism Depositary and deposited with the deposit number FERM BP-11081.
- Monoclonal antibodies produced by these hybridomas can be used as immunoassays for qualitative and quantitative analysis of IFN ⁇ 8 and its mutant proteins and as antibodies for purification of these proteins.
- RIFN ⁇ 8 used as an antigen was diluted to 2 ⁇ g / ml with a protein concentration of 50 ⁇ l / well (rIFN ⁇ 8 protein mass: 100 ng / 50 ⁇ l / well) and added to the Covalent NH module (sold by NUNC).
- o-PD o-phenylenediamine
- rIFN ⁇ 8 antibody-producing hybridoma ⁇ Preparation of rat anti-IFN ⁇ 8 antibody-producing hybridoma>
- the rIFN ⁇ 8 used in Example 1 was mixed with complete Freund's adjuvant as an antigen in the abdominal cavity of a 10-week-old BN rat, and the protein amount was immunized intraperitoneally at a rate of 20 ⁇ g / animal. Thereafter, the same amount of antigen was mixed with incomplete adjuvant every two weeks and inoculated twice, and one week after the last administration, the same amount of antigen without adjuvant was further intravenously injected. Three days later, the spleen was removed and dispersed to obtain splenocytes.
- the spleen cells and rat myeloma-derived Y3Ag1.2.3 cells were added to serum-free RPMI1640 medium (pH 7.2) pre-warmed to 37 ° C., and the cell density was 2.5 ⁇ 10 5. number / ml and 5 ⁇ 10 4 cells were suspended so that / ml, after centrifugation, was collected precipitate portion. 1 ml of serum-free RPMI 1640 medium (pH 7.2) containing 50% (w / v) polyethylene glycol having an average molecular weight of 1,500 daltons was added dropwise to this precipitate over 1 minute, followed by incubation at 37 ° C. for 1 minute.
- hybridoma ⁇ 8Y36-2 that is, mAb-IFN ⁇ 8Y36-2
- the hybridoma ⁇ 8Y36-2 was dated February 15, 2008, 1-1-1 Higashi 1-chome, Tsukuba, Ibaraki, Japan. National Institute of Advanced Industrial Science and Technology. Deposited at the Patent Biological Deposit Center and deposited under the deposit number FERM BP-11082.
- Monoclonal antibodies produced by these hybridomas can be used as antibodies for immunoassays for qualitative and quantitative determination of IFN ⁇ 8 and its mutant proteins and for purification of these proteins.
- monoclonal antibodies produced by these hybridomas are involved in the onset or exacerbation of IFN ⁇ 8 as it is or by using recombinant technology or the like to prepare chimeric antibodies, humanized antibodies or human antibodies. It can also be used as an active ingredient of therapeutic agents for various diseases.
- ⁇ Preparation of rat-mouse anti-IFN ⁇ 8 antibody-producing heterohybridoma> The same rIFN ⁇ 8 protein used in Experiment 1 was mixed into the abdominal cavity of 10-week-old BN rats in a complete Freund's adjuvant and immunized intraperitoneally at a protein amount of 20 ⁇ g / animal. Thereafter, the same amount was boosted twice every two weeks, and the same amount was further intravenously administered one week after the last immunization. Three days later, the spleen was removed and dispersed to obtain splenocytes.
- the spleen cells and mouse myeloma-derived SP2 / O-Ag14 cells were added to serum-free RPMI 1640 medium (pH 7.2) pre-warmed to 37 ° C., respectively, with a cell density of 2.5 ⁇ 10 5.
- the suspension was suspended at 5 ⁇ 10 4 cells / ml and centrifuged, and the precipitate was collected.
- 1 ml of serum-free RPMI 1640 medium (pH 7.2) containing 50% (w / v) polyethylene glycol having an average molecular weight of 1,500 daltons was added dropwise to this precipitate over 1 minute, followed by incubation at 37 ° C. for 1 minute.
- hybridoma clones ⁇ 8 # S18-1 and ⁇ 8 # S56-1 which stably produced the monoclonal antibody of the present invention.
- monoclonal antibodies can be used as antibodies for immunoassay for qualitative and quantitative determination of IFN ⁇ 8 and its mutant proteins and for purification of these proteins.
- monoclonal antibodies produced by these hybridomas are involved in the onset or exacerbation of IFN ⁇ 8 as it is or by using recombinant technology or the like to prepare chimeric antibodies, humanized antibodies or human antibodies. It can also be used as an active ingredient of therapeutic agents for various diseases.
- Hybridoma clones ⁇ 8 # 44, ⁇ 8 # 59, ⁇ 8 # 98, ⁇ 8 # 139 (Patent Biodeposition Center, National Institute of Advanced Industrial Science and Technology, accession number FERM BP-11081) and ⁇ 8 # obtained by the method of Example 1 145 is a serum-free medium (sold by Invitrogen, trade name “Hybridoma-SFM Complete DMP”) or 10% (v / v) fetal bovine serum so that each cell density is about 1 ⁇ 10 6 cells / ml.
- the suspension was suspended in RPMI1640 medium supplemented with (FCS), and cultured at 37 ° C. in a 5% (v / v) CO 2 incubator while expanding the culture scale.
- FCS RPMI1640 medium supplemented with
- hybridomas, pre, pristane into the peritoneal cavity of BALB / c mice of 8 weeks old, which had been injected 0.5 ml / mouse intraperitoneally, each 1 ⁇ 10 7 cells /
- the mice were inoculated and bred for 10 days in the usual manner. Ascites was collected from the mice, diluted 3 times with PBS, ammonium sulfate was added to 50% saturation, allowed to stand at 4 ° C. for 24 hours, centrifuged, and the precipitate was collected.
- the precipitate is dialyzed against PBS and applied to a protein G-coupled Sepharose column (sold by GE Healthcare Biosciences, trade name “Protein G Sepharose 4FF column”) to purify the IgG fraction. did.
- anti-IFN ⁇ 8 produced by hybridoma clones ⁇ 8 # 44, ⁇ 8 # 59, ⁇ 8 # 98, ⁇ 8 # 139 (National Institute of Advanced Industrial Science and Technology, Patent Biodeposition Center, accession number FERM BP-11081), ⁇ 8 # 145
- the antibodies are called ⁇ 8 # 44 mAb, ⁇ 8 # 59 mAb, ⁇ 8 # 98 mAb, ⁇ 8 # 139 mAb, and ⁇ 8 # 145 mAb, respectively.
- Hybridomas ⁇ 8 # Y19-1 and ⁇ 8Y36-2 obtained in Example 2 (National Institute of Advanced Industrial Science and Technology, Patent Biological Deposit Center, accession number FERM BP-11082), hybridoma ⁇ 8 # S18-1 obtained in Example 3 And ⁇ 8 # S56-1 to a cell density of about 1 ⁇ 10 6 cells / ml, respectively, a serum-free medium (sold by Invitrogen, trade name “Hybridoma-SFM Complete DMP”) or 10% ( v / v) Suspended in RPMI 1640 medium supplemented with fetal calf serum (FCS) and cultured in a 5% (v / v) CO 2 incubator at 37 ° C.
- FCS fetal calf serum
- the culture supernatant is collected, concentrated, and subjected to a protein G-Sepharose 4FF column (sold by GE Healthcare Bioscience) by an ordinary method, and the IgG fractions produced by each hybridoma are collected. Was purified.
- hybridomas ⁇ 8 # Y19-1, ⁇ 8Y36-2 Patent Biodeposition Center, National Institute of Advanced Industrial Science and Technology, accession number FERM BP-11082
- anti-products produced by hybridomas ⁇ 8 # S18-1 and ⁇ 8 # S56-1 The IFN ⁇ 8 antibody is called ⁇ 8 # Y19-1 mAb, ⁇ 8Y36-2 mAb, ⁇ 8 # S18-1 mAb, and ⁇ 8 # S56-1 mAb, respectively.
- FIG. 1 shows a Western blotting pattern when using the culture supernatant of ⁇ 8 # 139 using the IFN ⁇ s shown in FIG. Furthermore, an equal amount of a culture supernatant of these hybridomas and a solution obtained by diluting the IFNs or IFN ⁇ 8 mutants shown in Table 3 to 30 to 70 IU / ml are mixed to neutralize the antiviral activity ( Whether or not the activity decreased) was confirmed by measuring the antiviral activity using Sindbis virus cytopathy on FL cells as an index. The results are shown in Table 3. In Western blotting, the case where the band of IFNs or TNF protein was stained was determined to be reactive (+), and the case where it was not stained was determined to be non-reactive (-).
- the neutralization activity was determined to be neutrality activity (+) when the antiviral activity was not substantially measured, and to have no neutralization activity ( ⁇ ) otherwise.
- ⁇ Western blotting analysis> After adding rIFN ⁇ 8 or nIFN ⁇ 2 used as an antigen in Example 1 to a mixed solution consisting of 0.5 ml of 10% (w / v) SDS aqueous solution and 1 ml of glycerol and incubating at 37 ° C. for 1 hour, the amount of each protein was 10 or 100 ng. / The lane was charged and subjected to SDS-polyacrylamide gel electrophoresis.
- Proteins contained in a gel in the range of about 20 to 29 kilodaltons (hereinafter abbreviated as “KDa”) corresponding to the molecular weight of IFNs are transferred to a nitrocellulose membrane by a conventional method, and nonspecific In order to suppress the reaction, it was immersed in a blocking solution (Dainippon Sumitomo Pharma Co., Ltd., trade name “Block Ace”).
- KDa kilodaltons
- This blocking nitrocellulose membrane was immersed in a solution containing 2 ⁇ g / ml of any of 9 types of monoclonal antibodies purified using protein G sepharose at room temperature for 1 hour, and then 0.05% (v / v ) The excess antibody was removed by washing with 50 mM Tris-HCl buffer (pH 7.5) containing Tween 20.
- the nitrocellulose membrane was immersed in an HRP-labeled anti-mouse immunoglobulin or anti-rat immunoglobulin (both sold by DAKO Cytomation) for 1 hour at room temperature.
- the membrane was washed with 50 mM Tris-HCl buffer (pH 7.5) containing 0.05% (v / v) Tween 20 for 30 minutes, and then the color development reaction was performed using a commercially available Western blotting detection kit (GE Healthcare Biosciences). Sales, product name “ECL Western blotting detection reagent and Hyperfilm ECL”).
- the molecular weight markers include commercially available molecular weight markers for SDS-PAGE (sold by Bio-Rad, trade name “Prestain SDS-PAGE Standard Broad Range”, composition: myosin (204 KDa), ⁇ -galactosidase (120 KDa), BSA ( 100 KDa), ovalbumin (52 KDa), carbonic anhydrase (37 KDa), soybean trypsin inhibitor (29 KDa), lysozyme (20 KDa) and aprotinin (7 KDa).
- the monoclonal antibodies obtained in Examples 1 to 3 were all IgG class antibodies (light chain is ⁇ ). Further, as is clear from Tables 1 and 2, these antibodies react only with rIFN ⁇ 8, nIFN ⁇ 8 and two types of IFN ⁇ 8 mutant proteins, and other human IFN ⁇ subtypes, IFN ⁇ , IFN ⁇ , ConIFN, mouse IFN ⁇ / ⁇ , It became clear that these antibodies did not react with rat IFN ⁇ and TNF ⁇ , and these antibodies specifically recognize IFN ⁇ 8 and its mutants. As is clear from FIG.
- ⁇ Construction of an enzyme immunoassay system for IFN ⁇ 8> Using 9 types of monoclonal antibodies prepared by the method of Example 4, screening of antibodies suitable for construction of an enzyme immunoassay system capable of specifically quantifying IFN ⁇ 8 was performed as follows.
- ⁇ Antibody> Nine types of monoclonal antibodies prepared in Example 4, rabbit polyclonal anti-IFN ⁇ antibody (hereinafter abbreviated as “polyIFN ⁇ ”) and mouse monoclonal anti-IFN ⁇ antibody (hereinafter abbreviated as “mAbIFN ⁇ 14”) (all are stocks) Company Hayashibara Biochemical Laboratories) was used. In addition, polyIFN ⁇ and mAbIFN ⁇ 14 have reactivity with IFN ⁇ 8 and other human IFN ⁇ subtypes.
- the 11 kinds of antibodies were labeled with HRP by the periodate oxidation method. That is, 10 mg of HRP (sold by Roche) was dissolved in 2 ml of distilled water, 125 ⁇ l of 0.1 M sodium periodate was added, and the mixture was allowed to stand at room temperature for 15 minutes in the dark. Thereafter, 100 ⁇ l of ethylene glycol was added, dialyzed against 1 mM sodium acetate buffer (pH 4.2) for 5 minutes at room temperature in the dark, and then concentrated so that HRP was 15 mg / ml or more.
- HRP sold by Roche
- bovine serum albumin (hereinafter abbreviated as “BSA”) is dissolved to 1%, membrane filtered (pore size is 0.22 ⁇ m), and HRP-labeled antibody (hereinafter “labeled antibody”) is obtained. ”) was prepared.
- BSA bovine serum albumin
- labeled antibody HRP-labeled antibody
- the 11 types of HRP-labeled antibodies and 11 types of unlabeled antibodies (hereinafter referred to as “unlabeled antibodies”) used for the labeling were used as solid-phase antibodies, and 121 combinations by the sandwich method were used. It was tested whether rIFN protein could be quantified by enzyme immunoassay.
- each well was washed 3 times with PBS containing 0.05% Tween 20. After removing PBS used for washing, the 11 kinds of labeled antibodies were diluted to 1 ⁇ g / ml with PBS each containing 5% FCS, 1% BSA, 0.15 M NaCl and 0.1% CHAPS. Each was added 50 ⁇ l / well to a well in which 11 types of unlabeled antibodies were used as solid phases, and shaken at room temperature for 2 hours.
- required the average.
- the minimum concentration of rIFN ⁇ 8 protein in which the correlation coefficient (r value) for determining linearity by regression analysis of the calibration curve based on the measured absorbance is in the range of 0.997 or more, and the absorbance when the control well is measured.
- the value obtained by adding 3 times the standard deviation of the measured value to (OD) and the value obtained by subtracting the value obtained by multiplying the standard deviation of the measured value by 3 from the measured value of the minimum concentration of rIFN ⁇ 8 protein Then, the rIFN ⁇ 8 protein concentration corresponding to the larger value was taken as the lower detection limit concentration of rIFN ⁇ 8 protein by the tested enzyme immunoassay.
- mAbIFN ⁇ 14 or polyIFN ⁇ when used as a labeled antibody, these antibodies may react with IFN ⁇ subtypes other than IFN ⁇ 8. Therefore, an enzyme immunoassay system specific to IFN ⁇ 8 subtype is ⁇ 8 # 139 mAb as a solid phase antibody. And the combination using ⁇ 8Y36-2 mAb as the labeled antibody was judged to be particularly desirable.
- the rIFN ⁇ 8 protein concentration corresponding to the maximum OD value in the range where the correlation coefficient (r value) indicating the linearity of the calibration curve is 0.997 or more is obtained, and the upper limit concentration of rIFN ⁇ 8 protein detected by the enzyme immunoassay is determined. It shows together with Table 5.
- ⁇ Method of enzyme immunoassay> ⁇ 8 # 139 mAb as a solid phase antibody was diluted to 20 ⁇ g / ml with PBS, and dispensed at 100 ⁇ l / well onto an immunoplate (sold by NUNC). After allowing to stand at room temperature for 3 hours, the solid phase solution was discarded, PBS containing 1% BSA was added at 250 ⁇ l / well, and the plate was allowed to stand at 4 ° C. overnight for blocking. After removing PBS containing 1% BSA, prepare a standard solution by diluting rIFN ⁇ 8 to 10 to 2,000 pg / ml with PBS containing 2.5% FCS, 0.5% BSA and 0.5M NaCl. did.
- rIFN ⁇ 8 was 0.05 to 2 ng / ml (50 to 2 ng / ml). In the range of 1,000 pg / ml), a linear increase in absorbance proportional to the protein mass was observed. This result indicates that the protein at a concentration of at least about 50 to 2,000 pg / ml can be detected with high accuracy by using the enzyme immunoassay system.
- the enzyme immunoassay system allows any one of nIFN ⁇ 8, rIFN ⁇ 8 and IFN ⁇ subtypes other than mutants thereof, IFN ⁇ , IFN ⁇ , Con IFN, rat IFN ⁇ , mouse IFN ⁇ / ⁇ , TNF ⁇ , Even when a solution containing 10 ng / ml corresponding to 200 times the detection lower limit concentration of IFN ⁇ 8 (5 times the upper detection limit concentration) is measured, the absorbance is different from the case of only the buffer solution in which these proteins are dissolved. I was not able to admit. This result indicates that the enzyme immunoassay has no cross-reactivity with IFNs other than IFN ⁇ 8 and its mutants and cytokines, and an enzyme immunoassay system specific to IFN ⁇ 8 and its mutants has been established.
- ⁇ Detection of rIFN ⁇ 8 protein by radioimmunoassay> ⁇ 8 # 139 mAb obtained by the method of Example 4 was adsorbed to polystyrene beads for radioimmunoassay by a conventional method and allowed to stand overnight at 4 ° C. in PBS containing 2% (w / v) BSA. Thus, solid phase antibody beads were prepared.
- nIFN ⁇ 8 protein derived from BALL-1 cells by enzyme immunoassay> NIFN ⁇ induced by adding HVJ to BALL-1 cells (owned by Hayashibara Biochemical Laboratories Co., Ltd.), a human lymphoblastoid cell line, is a ratio of 72 ⁇ 9: 28 ⁇ 9 between nIFN ⁇ 2 and nIFN ⁇ 8 (IFN ⁇ 8b). It is known that it contains a small amount of nIFN ⁇ 7 (for example, Shigeharu Fukuda et al., “Lymphokine”, Vol. 7, No. 2, 175 thru 185 (1988)).
- BALL-1 cells were transplanted subcutaneously in the back of hamster neonates, and the proliferated BALL-1 cells were suspended in RPMI 1640 medium, and HVJ was added and cultured overnight.
- HVJ inactivated solution hereinafter abbreviated as “BALL-1 culture supernatant”
- human nIFN ⁇ purified from the solution with a monoclonal antibody column (trade name “NK2-Sepharose” sold by Lonza).
- the samples were subjected to bioassay and enzyme immunoassay specific for IFN ⁇ 2 or IFN ⁇ 8.
- the results are shown in Table 6.
- Table 6 also shows the results of measuring the activity of a preparation in which the anti-IFN ⁇ 8 antibody ( ⁇ 8 # 139 mAb) prepared in Example 4 was previously added to specifically neutralize the activity of nIFN ⁇ 8.
- the enzyme immunoassay the assay system constructed in Example 6 was used for quantification of nIFN ⁇ 8, and a commercially available IFN ⁇ assay kit (trade name “human IFN- ⁇ measurement kit”, sold by JIMRO Co., Ltd.) was used for nIFN ⁇ 2. did.
- the measurement used 3 wells per sample, and calculated
- human nIFN ⁇ contained in the BALL-1 culture supernatant was calculated as nIFN ⁇ 8 in the bioassay with about 38% of the total human IFN ⁇ activity.
- nIFN ⁇ 8 human nIFN ⁇ 8 in the bioassay with about 38% of the total human IFN ⁇ activity.
- the same culture supernatant was measured by an enzyme immunoassay specific for nIFN ⁇ 2 and nIFN ⁇ 8, about 40% of the total human IFN ⁇ activity was calculated as nIFN ⁇ 8.
- the sample obtained by purifying the BALL-1 culture supernatant with an antibody column about 37% of the total human IFN ⁇ activity was calculated as IFN ⁇ 8 in the bioassay.
- nIFN ⁇ derived from BALL-1 cells
- nIFN ⁇ 8 mutant protein Human nIFN ⁇ (containing 6.46 ⁇ g of nIFN ⁇ 2 and 1.81 ⁇ g of nIFN ⁇ 8), IFN ⁇ 8-MUT2 (containing 5.83 ⁇ g) or IFN ⁇ 8-MUT3 (containing 5.38 ⁇ g) used in Example 6, 4 BALB / c mice (Nihon Charles River Co., Ltd., female, 9 weeks old) were subcutaneously administered at about 10 6 IU / animal. After administration, blood was sampled from the tail vein over time (0, 0.5, 1, 2, 3, 6, 24 hours), and the plasma obtained after centrifugation was the same as that used in Example 8.
- nIFN ⁇ 8 contained in human nIFN ⁇ is less than one third of nIFN ⁇ 2, but when human nIFN ⁇ is administered subcutaneously to mice, nIFN ⁇ 8 is less pharmacokinetic than nIFN ⁇ 2.
- the constant AUC was 3.6 times ( ⁇ 1975 ⁇ 553), and the MRT was 1.7 times ( ⁇ 3.9 ⁇ 2.4). It was also found that the blood kinetics of the IFN ⁇ 8 mutant protein resembles nIFN ⁇ 2 rather than nIFN ⁇ 8 when viewed from MRT and EBA.
- a water-insoluble carrier trade name “CNBr-activated Sepharose 4B”, sold by GE Healthcare Biosciences Inc.
- the collected fractions were pooled, concentrated, and then the protein content was measured. As a result, it was found that a purified protein having a purity of 99.8% or more was obtained. Further, when this purified protein was subjected to IFN ⁇ 2 or IFN ⁇ 8-specific enzyme immunoassay used in Example 8, no IFN ⁇ 2 protein was detected, and only IFN ⁇ 8 was detected. The amount of protein was in good agreement with the antiviral activity of the purified protein considering the specific activity of nIFN ⁇ 8, and almost all of nIFN ⁇ 8 contained in human nIFN ⁇ loaded on the column was recovered. The antibody column was found to be suitable for IFN ⁇ 8 purification.
- RNA preparation kit (sold by QIAGEN, trade name “RNeasy Mini Kit (Cat. No. 74104)”) was used to extract RNA from cell homogenates according to “total RNA purification from animal cells using centrifugation” in the instruction manual to obtain 30 to 60 ⁇ g of RNA.
- the cell homogenate was prepared using a commercially available column (available from QIAGEN, trade name “QIAshredder Spin Column”), and DNAase I treatment was not performed.
- RNA reverse transcriptase reaction and PCR reaction were carried out using a commercially available kit (trade name “SuperScript III reverse transcriptase (catalog number 18080-044)” sold by Invitrogen) and its instruction manual “First Strand cDNA Synthesis”.
- the reverse transcriptase reaction was carried out using commercially available oligo (dT) 12-18 (available from Invitrogen, catalog number 18418-012) as a primer.
- a PCR reaction was performed using a commercially available Mouse Ig-Primer set (available from Novagen, catalog number # 69831-3) as a primer.
- KOD kit As the DNA polymerase, a commercially available product (sold by TOYOBO, trade name “KOD-Plus- (catalog number KOD-201)”, hereinafter referred to as “KOD kit”) was used, and amplification was not possible with this KOD kit.
- the product name is “TaKaRa Ex Taq (code RR001A)” sold by Takara Bio Inc., hereinafter referred to as “Ex Taq kit”. )It was used.
- the tube is repeatedly treated 30 to 35 times at three temperature cycles of 94 ° C., 1 minute, treatment temperature *, 1 minute, 72 ° C., 1 minute, and cooled to 4 ° C.
- Treatment temperature *; 5′A and B Leader primers were 50 ° C., and 5 ′ CG Leader primer was 60 ° C.
- the purified DNA fragment obtained was ligated to pPCR-Script Cam SK (+) Vector using Stratagene PCR-Script Cam Cloning Kit (# 211192), and transformed into competent cell XL10-Gold of the same kit. . Subsequently, after seeding on a plate containing X-gal, chloramphenicol and IPTG, white colonies were picked up, and clones containing inserts of the desired size were selected by colony direct PCR.
- a plasmid was prepared from a culture solution of a colony containing a fragment of the desired size using a commercially available plasmid preparation kit (sold by QIAGEN, trade name “QIAprep spin Miniprep Kit (Cat No. 27106))”. The reaction conditions for the colony direct PCR method are shown below.
- the DNA base sequence was a DNA automatic sequencer (trade name “CEQ8000”, sold by BECKMAN COULTER), a vector T3 primer (5′AATTAACCCTCACTAAAGGG3 ′: SEQ ID NO: 1 in the sequence listing), and a T7 primer (5′GTATATACGCACTCACTATAGGGC3 ′: Sequencing reaction was performed in both directions using SEQ ID NO: 2) in the sequence listing to obtain 3 clones containing DNA encoding heavy chain variable region and 3 clones containing DNA encoding light chain variable region Thus, the base sequence of the DNA was determined.
- CEQ8000 DNA automatic sequencer
- T3 primer 5′AATTAACCCTCACTAAAGGG3 ′: SEQ ID NO: 1 in the sequence listing
- a T7 primer 5′GTATATACGCACTCACTATAGGGC3 ′: Sequencing reaction was performed in both directions using SEQ ID NO: 2) in the sequence listing to obtain 3 clones containing DNA encoding heavy chain variable region and 3 clones containing DNA
- amino acid sequences Based on the base sequences of the above three DNAs, the results of estimating the amino acid sequences including the heavy chain and light chain variable region of ⁇ 8 # 139 mAb following the amino acid sequence of the 5 ′ primer portion used for cloning, The amino acid sequences are shown in SEQ ID NOs: 6 to 8 in the sequence listing.
- amino acid at the carboxy terminus of the heavy chain and the light chain is determined based on the amino acid sequence at the amino terminus of the known heavy chain and light chain constant region, and the amino acid in the variable region of the heavy chain and light chain of ⁇ 8 # 139 mAb The sequence was determined and shown in the amino acid sequences shown in SEQ ID NOs: 9 to 11 in the sequence listing.
- amino acid sequence represented by SEQ ID NO: 10 in the sequence listing among the amino acid sequences represented by SEQ ID NO: 9 in the sequence listing, the 37th phenylalanine (Phe) from the amino terminus is isoleucine (Ile) and the 79 th isoleucine ( Ile) had a sequence substituted with threonine (Thr).
- the amino acid sequence of the heavy chain variable region of ⁇ 8 # 139 mAb has the amino acid sequence shown by SEQ ID NO: 9 in the sequence listing, and some antibodies are represented by SEQ ID NO: 10 in the sequence listing. It tells you that it has the amino acid sequence shown.
- amino acid sequences Based on the nucleotide sequences of the above three DNAs, the results of estimating the amino acid sequences including the heavy chain and light chain variable region of ⁇ 8Y36-2 mAb following the amino acid sequence of the 5 ′ primer portion used for cloning, The amino acid sequences are shown in SEQ ID NOs: 15 to 17 in the sequence listing. Further, the amino acid at the carboxy terminus of the heavy chain and the light chain is determined based on the amino acid sequence at the amino terminus of the known heavy chain and light chain constant region, and the amino acid in the variable region of the heavy chain and light chain of ⁇ 8Y36-2 mAb The sequence was determined and shown in the amino acid sequences shown in SEQ ID NOs: 18 to 20 in the sequence listing.
- the amino acid sequence represented by SEQ ID NO: 19 in the sequence listing is a sequence in which the 19th glycine (Gly) from the amino terminus of the amino acid sequence represented by SEQ ID NO: 18 in the sequence listing is substituted with aspartic acid (Asp). Had. From the number of clones obtained, the amino acid sequence of the heavy chain variable site of ⁇ 8Y36-2 mAb has the amino acid sequence shown by SEQ ID NO: 18 in the sequence listing, and some antibodies are represented by SEQ ID NO: 19 in the sequence listing. It tells you that it has the amino acid sequence shown.
- Examples 12 and 13 were obtained by using the base sequences and amino acid sequences of the variable regions of the heavy and light chains of ⁇ 8 # 139 mAb and ⁇ 8Y36-2 mAb, and using the partial sequences as they were.
- a recombinant is prepared by deleting, adding, or substituting about 1 to 100 of these amino acids, and human IFN ⁇ 8 and its mutant protein are specifically recognized.
- Purification of IFN ⁇ 8, and further, chimeric antibodies, humanized antibodies, or human antibodies used as therapeutic agents for IFN ⁇ 8-related diseases, clinical diagnostic agents, etc. can be obtained by known methods (for example, JP-A-2004-533217 and 2007-252372) shows that it can also be advantageously carried out.
- the hypervariable sites of the heavy chain of ⁇ 8 # 139 mAb are the amino acid sequences shown in SEQ ID NOs: 21 to 23 in the sequence listing, respectively, and the hypervariable sites of the light chain are the amino acids shown in SEQ ID NOs: 24 to 26 in the sequence listing, respectively. It turned out to be an array.
- the hypervariable sites of ⁇ 8Y36-2 mAb heavy chain and light chain are the amino acid sequences shown in SEQ ID NOs: 27 to 29 in the sequence listing, respectively, and the hypervariable sites of the light chain are SEQ ID NOS: 30 to 32 in the sequence listing, respectively. It became clear that it is an amino acid sequence shown by.
- a recombinant is prepared by adding about 1 to 100 amino acids, and further deleting, adding, or substituting amino acids at hypervariable sites as appropriate, and specifically recognizes human IFN ⁇ 8 and its mutant protein. Quantitative and qualitative analysis of IFN ⁇ 8, purification of IFN ⁇ 8, and preparation of chimeric, humanized, or human antibodies suitable for use as therapeutic agents for IFN ⁇ 8-related diseases, clinical diagnostic agents, etc. It tells you what you can do.
- This product is useful as a therapeutic agent for various diseases in which IFN ⁇ 8 is involved in onset or exacerbation.
- Each of these 9 dry preparations was dissolved in physiological saline, and each preparation was dissolved in 5 rats (average body weight 123 g / animal) once a day for 7 days, 5 ml / animal (as a monoclonal antibody). (750 mg / animal / dose) administered intraperitoneally and body weight was measured daily.
- 5 rats (average body weight 127 g / animal) were intraperitoneally administered with saline 5 ml / animal once daily for 7 days, and body weight was measured daily.
- no difference from the control was observed when any preparation was administered.
- no abnormalities were observed in the rats to which the preparations were administered and the control rats.
- ⁇ Therapeutic agent> The base sequence (SEQ ID NO: 3 to 5 in the sequence listing) encoding the region containing the heavy chain and light chain variable sites of ⁇ 8 # 139 mAb obtained in Example 12 and the amino acid sequence of the variable site (SEQ ID NO: 9 to sequence listing in the sequence listing) 11), a humanized antibody is prepared by a conventional method, purified to a purity of 99.98% or higher, and the antibody is 200 mg / ml, ⁇ , ⁇ -trehalose (manufactured by Hayashibara Biochemical Laboratories, Inc., pyrogen-free).
- mice This product was dissolved in physiological saline and intravenously administered to 5 mice (average body weight 23 g / animal) once a day for 7 days, 0.5 ml / animal (100 mg / animal / times as a monoclonal antibody) Dosage and body weight was measured daily.
- 5 mice As a control, 5 mice (average body weight 24 g / animal) were intravenously administered with physiological saline 0.5 ml / mouse once daily for 7 days, and body weight was measured daily.
- body weights of mice administered with this product and control mice were compared, no difference was observed. In addition, no abnormalities were observed in the mice to which this product was administered and in the control mice even by visual observation.
- ⁇ Therapeutic agent> A base sequence (SEQ ID NO: 12 to 14 in the sequence listing) encoding the region containing the heavy chain and light chain variable sites of ⁇ 8Y36-2 mAb obtained in Example 13 and its amino acid sequence (SEQ ID NO: 18 to 20 in the sequence listing) Based on the above, a humanized antibody was prepared by a conventional method, purified to 99.98% or higher, and then 200 mg / ml, ⁇ , ⁇ -trehalose (manufactured by Hayashibara Biochemical Laboratories, Inc., pyrogen-free) 140 ml / ml, L-histidine hydrochloride 3.4 mg / ml, L-histidine 2.2 mg / ml, and Tween 20 dissolved in purified water to 0.6 mg / ml.
- the lyophilized preparation was prepared by a conventional method.
- This product can be used as an injection by dissolving in physiological saline at the time of use.
- This product is useful as a therapeutic agent for various diseases in which IFN ⁇ 8 is involved in onset or exacerbation.
- This product was dissolved in physiological saline and intravenously administered to 5 mice (average body weight 23 g / animal) once a day for 7 days, 0.5 ml / animal (100 mg / animal / times as a monoclonal antibody) Dosage and body weight was measured daily.
- 5 mice (average body weight 23 g / animal) were intravenously administered with physiological saline 0.5 ml / animal once daily for 7 days, and body weight was measured daily.
- no difference was observed.
- no abnormalities were observed in the mice to which this product was administered and in the control mice even by visual observation.
- the monoclonal antibody of the present invention specifically reacts with IFN ⁇ 8 and its mutant protein. Therefore, the monoclonal antibody of the present invention has a wide variety of uses for the detection and purification of such IFN ⁇ 8 and mutant proteins thereof.
- Such a useful monoclonal antibody of the present invention can be easily obtained in a desired amount by a production method using a hybridoma.
- the present invention exhibits such remarkable operational effects, and it can be said that it is a very significant invention to contribute to the world.
Abstract
Description
<抗原>
抗原として、国際公開第WO 2006/051805号パンフレットに記載された方法により調製したIFNα8bのアミノ酸配列を有するrIFNα8(大腸菌由来、蛋白質濃度510μg/ml、1.27×108IU/ml)を使用した。なお、IFNの力価(国際単位:IU)は、FL細胞のシンドビスウイルスによる細胞変性の抑制作用を指標とするバイオアッセイで測定した。測定には、国際標準品(Ga23-901-532)を使用して検定した自社標準品(株式会社林原生物化学研究所調製)を使用した。
<免疫方法>
抗原(10μg/匹)とフロイントのコンプリートアジュバント(株式会社ディフコ(DIFCO)販売)とを混合して、エマルジョンを作成し、マウス(BALB/c、9週齢、メス、株式会社日本チャールスリバー販売)に、腹腔内に免疫した。2回目以降はフロイントのインコンプリートアジュバント(株式会社ディフコ(DIFCO)販売)に変更して、腹腔内に2週間隔で計3回免疫した。
<細胞融合>
最後の免疫後、7日目に尾静脈より部分採血し抗体価を確認した。抗体価の上昇が認められた個体について、細胞融合を行う3日前に、最終免疫として、アジュバントを含まない抗原10μgを静脈内に投与(以下、「静注」という。)した。この静注を行って3日目のマウスの脾臓を、常法により採取し、分散して脾細胞を得た。この脾細胞と親株であるマウスSP2/O-Ag14細胞(ATCC CRL1581)を37℃に予温しておいた血清不含のRPMI1640培地(pH7.2)にそれぞれ細胞密度2.5×105個/ml及び5×104個/mlになるように浮遊させ、遠心分離後、沈澱部を採取した。この沈澱に平均分子量1,500ダルトンの50%(w/v)ポリエチレングリコールを含む血清不含のRPMI1640培地(pH7.2)1mlを1分間かけて滴々加え、37℃で1分間インキュベートした後、全量が50mlになるまで血清不含のRPMI1640培地(pH7.2)を滴々加え、遠心分離後、沈澱部を採取した。この沈澱をHAT培地に浮遊させ、96ウエルマイクロプレートに200μl/ウエルずつ分注し、37℃で2週間インキュベートしてハイブリドーマを選択した。細胞融合は、1回に1匹のマウスから得た脾細胞を使用して、同様の方法で3回実施した。ハイブリドーマが増殖した各ウエルの培養上清(以下、「ハイブリドーマの培養上清」という。)を採取し、後述の直接法によるエンザイムイムノアッセイに供して、rIFNα8に反応性を示す抗体を産生するハイブリドーマを選別した。引続き、このハイブリドーマを、常法にしたがって限界希釈を繰返し適用し、rIFNα8に親和性を示すモノクローナル抗体を安定して産生するハイブリドーマのクローンα8#44、α8#59、α8#98、α8#139、α8#145を得た。なお、ハイブリドーマα8#139、すなわち、mAb-IFNα8#139については、平成20年2月15日付で、日本国茨城県つくば市東1丁目1番地1 中央第6所在の独立行政法人産業技術総合研究所 特許生物寄託センターに寄託し、受託番号FERM BP-11081として受託された。これらのハイブリドーマの産生するモノクローナル抗体は、IFNα8及びその変異蛋白質の定性や定量のためのイムノアッセイ用やこれらの蛋白質の精製用の抗体として使用することができる。また、これらのハイブリドーマの産生するモノクローナル抗体は、そのままで、或いは、組換技術等を利用して、キメラ抗体、ヒト化抗体やヒト抗体を調製して、IFNα8が発症や増悪に関与している各種疾患の治療剤の有効成分としても使用することができる。
<直接法による抗IFNα8抗体産生ハイブリドーマのスクリーニング>
抗原として使用したrIFNα8を、その蛋白質濃度を2μg/mlに希釈して、50μl/ウエル(rIFNα8の蛋白質量:100ng/50μl/ウエル)で、コバレントNHモジュール(NUNC社販売)に加え、ビス スルフォサクシニミジル スベレイトを用いて吸着させて固相とした。各ウエルに加えたrIFNα8を含む溶液を除去し、1%BSA含PBSでブロッキング処理後、処理液を除去した。この各ウエルに、上記のハイブリドーマの培養上清を加えて、室温で2時間振とうした。この培養上清を除去後、0.05%ツイーンを含むPBSで洗浄し、ペルオキシダーゼ(以下、「HRP」と略記する。)標識したウサギ抗マウスイムノグロブリン(ダコ サイトメイション(DAKO Cytomation)社販売)を加えた。この標識抗体を含む溶液を除去後、0.05%ツイーンを含むPBSで洗浄し、0.5mg/mlのo-フェニレンジアミン(以下、「o-PD」と略記する。)と0.03%の過酸化水素を含む0.1Mのリン酸ナトリウム-クエン酸緩衝液(pH5.0)を加えて、発色反応を行い、2N H2SO4を100μl/ウエル加えて反応を停止して、マルチプレートリーダーで吸光度(OD:A490/650nm)を測定して、rIFNα8に反応性を示す抗体を産生するハイブリドーマを選別した。
10週齢BNラットの腹腔内に実施例1で使用したrIFNα8を抗原として、コンプリートフロイントアジュバントに混和して、その蛋白質量が20μg/匹の割合で腹腔内に免疫した。その後、2週間おきに同一量の抗原をインコンプリートアジュバントに混合して2回接種し、最後の投与から1週間後に、アジュバントを含まない抗原を、同一量さらに静注した。その3日後に脾臓を摘出し、分散して脾細胞を得た。この脾細胞とラット骨髄腫由来のY3Ag1.2.3細胞(ATCC CRL1631)を37℃に予温しておいた血清不含のRPMI1640培地(pH7.2)にそれぞれ細胞密度2.5×105個/ml及び5×104個/mlになるように浮遊させ、遠心分離後、沈澱部を採取した。この沈澱に平均分子量1,500ダルトンの50%(w/v)ポリエチレングリコールを含む血清不含のRPMI1640培地(pH7.2)1mlを1分間かけて滴々加え、37℃で1分間インキュベートした後、全量が50mlになるまで血清不含のRPMI1640培地(pH7.2)を滴々加え、遠心分離後、沈澱部を採取した。この沈澱をHAT培地に浮遊させ、96ウエルマイクロプレートに200μl/ウエルずつ分注し、37℃で2週間インキュベートしてハイブリドーマを選択した。各ウエルにおける培養上清中に分泌された抗体につき、後述のサンドイッチ法によるエンザイムイムノアッセイにより調べ、rIFNα8に反応性を示す抗体を産生するハイブリドーマを選別した。引続き、このハイブリドーマに常法にしたがって限界希釈を繰返し適用し、本発明のモノクローナル抗体を安定して産生するハイブリドーマのクローンα8#Y19-1及びα8Y36-2を得た。なお、ハイブリドーマα8Y36-2、すなわち、mAb-IFNα8Y36-2については、平成20年2月15日付で、日本国茨城県つくば市東1丁目1番地1 中央第6所在の独立行政法人産業技術総合研究所 特許生物寄託センターに寄託し、受託番号FERM BP-11082として受託された。これらハイブリドーマの産生するモノクローナル抗体は、IFNα8及びその変異蛋白質の定性や定量のためのイムノアッセイ用やこれらの蛋白質の精製用の抗体として使用することができる。また、これらのハイブリドーマの産生するモノクローナル抗体は、そのままで、或いは、組換技術等を利用して、キメラ抗体、ヒト化抗体やヒト抗体を調製して、IFNα8が発症や増悪に関与している各種疾患の治療剤の有効成分としても使用することができる。
<サンドイッチ法による抗IFNα8抗体産生ハイブリドーマのスクリーニング>
イムノプレート(NUNC社販売)を、ウサギ抗ラットイムノグロブリン(ダコ サイトメイション(DAKO Cytomation)社販売)でコーティングし、ハイブリドーマの培養上清を加えて、室温で1~2時間振とうし、培養上清を除去して、0.05%ツイーンを含むPBSで3回洗浄して、rIFNα8を5ng/50μl/ウエル添加し、さらにHRP標識したウサギポリクローナル抗IFNα抗体(株式会社林原生物化学研究所調製)を、50ng/50μl/ウエル加えた。実施例1と同様に、発色反応を行い、マルチプレートリーダーで吸光度(OD:A490nm/650nm)を測定して、rIFNα8に反応性を示す抗体を産生するハイブリドーマを選別した。
10週齢BNラットの腹腔内に、実験1で使用したものと同じrIFNα8蛋白質をコンプリートフロイントアジュバントに混和して、蛋白質量が20μg/匹の割合で腹腔内に免疫した。その後、2週間おきに同一量を2回追加免疫し、最後の免疫から1週間後に同一量をさらに静注した。その3日後に脾臓を摘出し、分散して脾細胞を得た。この脾細胞とマウス骨髄腫由来のSP2/O-Ag14細胞(ATCC CRL1581)を37℃に予温しておいた血清不含のRPMI1640培地(pH7.2)にそれぞれ細胞密度2.5×105個/ml及び5×104個/mlになるように浮遊させ、遠心分離後、沈澱部分を採取した。この沈澱に平均分子量1,500ダルトンの50%(w/v)ポリエチレングリコールを含む血清不含のRPMI1640培地(pH7.2)1mlを1分間かけて滴々加え、37℃で1分間インキュベートした後、全量が50mlになるまで血清不含のRPMI1640培地(pH7.2)を滴々加え、遠心分離後、沈澱部を採取した。この沈澱をHAT培地に浮遊させ、96ウエルマイクロプレートに200μl/ウエルずつ分注し、37℃で2週間インキュベートしてハイブリドーマを選択した。各ウエルにおける培養上清中に分泌された抗体につき、実施例1又は実施例2と同様の方法でIFNα8との反応性をエンザイムイムノアッセイにより調べ、rIFNα8に反応性を示す抗体を産生するハイブリドーマを選別した。引続き、このハイブリドーマに、常法にしたがって限界希釈を繰返し適用し、本発明のモノクローナル抗体を安定して産生するハイブリドーマのクローンα8#S18-1及びα8#S56-1を得た。これらのモノクローナル抗体は、IFNα8及びその変異蛋白質の定性や定量のためのイムノアッセイ用やこれらの蛋白質の精製用の抗体として使用することができる。また、これらのハイブリドーマの産生するモノクローナル抗体は、そのままで、或いは、組換技術等を利用して、キメラ抗体、ヒト化抗体やヒト抗体を調製して、IFNα8が発症や増悪に関与している各種疾患の治療剤の有効成分としても使用することができる。
<マウス抗IFNα8モノクローナル抗体の調製>
実施例1の方法により得たハイブリドーマのクローンα8#44、α8#59、α8#98、α8#139(独立行政法人産業技術総合研究所 特許生物寄託センター、受託番号FERM BP-11081)及びα8#145を、各々細胞密度約1×106個/mlになるように無血清培地(インビトロジェン(Invitrogen)社販売、商品名「ハイブリドーマ-SFMコンプリートDMP」)又は10%(v/v)ウシ胎児血清(FCS)を加えたRPMI1640培地に浮遊させ、培養規模を拡大しながら、5%(v/v)CO2インキュベータ中、37℃で培養した。所期の細胞密度に達した時点で、ハイブリドーマを、予め、プリスタンを0.5ml/匹腹腔内注射しておいた8週齢のBALB/cマウスの腹腔内に、各々1×107個/匹注射接種し、通常の方法で10日間飼育した。マウスから腹水を採取し、PBSで3倍希釈した後、硫酸アンモニウムを50%飽和になるように加え、4℃で24時間静置し、遠心分離後、沈澱部を採取した。沈殿をPBSで透析し、常法により、プロテインG結合セファロースカラム(ジーイー ヘルスケア バイオサイエンス(ジーイー ヘルスケア バイオサイエンス)社販売、商品名「プロテインGセファロース4FFカラム」)に供し、IgG画分を精製した。以下、ハイブリドーマのクローンα8#44、α8#59、α8#98、α8#139(独立行政法人産業技術総合研究所 特許生物寄託センター、受託番号FERM BP-11081)、α8#145の産生する抗IFNα8抗体を、各々α8#44mAb、α8#59mAb、α8#98mAb、α8#139mAb、α8#145mAbとよぶ。
<ラット或いはラット-マウス抗IFNα8モノクローナル抗体の調製>
実施例2で得たハイブリドーマα8#Y19-1及びα8Y36-2(独立行政法人産業技術総合研究所 特許生物寄託センター、受託番号FERM BP-11082)、実施例3で得たハイブリドーマα8#S18-1及びα8#S56-1を、各々、細胞密度約1×106個/mlになるように、無血清培地(インビトロジェン(Invitrogen)社販売、商品名「ハイブリドーマ-SFMコンプリートDMP」)又は10%(v/v)ウシ胎児血清(FCS)を加えたRPMI1640培地に浮遊させ、培養規模を拡大しながら、5%(v/v)CO2インキュベータ中、37℃で所定量の培養規模になるまで培養した。この培養上清を回収し、濃縮して、常法により、プロテインG-セファロース4FFカラム(ジーイー ヘルスケア バイオサイエンス(ジーイー ヘルスケア バイオサイエンス)社販売)に供し、各々のハイブリドーマの産生したIgG画分を精製した。以下、ハイブリドーマα8#Y19-1、α8Y36-2(独立行政法人産業技術総合研究所 特許生物寄託センター、受託番号FERM BP-11082)、ハイブリドーマα8#S18-1及びα8#S56-1の産生する抗IFNα8抗体を、各々α8#Y19-1mAb、α8Y36-2mAb、α8#S18-1mAb及びα8#S56-1mAbとよぶ。
<モノクローナル抗体の特徴>
これら9種類の抗体のイソタイプを、各ハイブリドーマを無血清培地で培養した培養上清を使用して、市販のエンザイムイムノアッセイキット(Zymed社販売、商品名「Rat MonoAB ID kit」又は「Mouse MonoAB ID kit」)により決定した結果を表1に示す。さらに、これら9種類のモノクローナル抗体の、表1又は2に示すIFN類及びTNFαに対する反応性を、後述のウエスタンブロッティング分析により確認した結果を表1及び表2に併せて示す。また、代表的なウエスタンブロッティングの結果として、図1に示すIFNα類を使用して、α8#139の培養上清を用いた時のウエスタンブロッティングのパターンを図1に示す。さらに、これらのハイブリドーマの培養上清と、表3に示すIFN類又はIFNα8の変異体を30乃至70IU/mlに希釈した溶液とを等量混合して、その抗ウイルス活性が中和される(活性が減少する)かどうかを、FL細胞に対するシンドビスウイルスの細胞変性を指標とする抗ウイルス活性測定により確認した。その結果を表3に示す。なお、ウエスタンブロッティングは、IFN類或いはTNF蛋白質のバンドが染色された場合を反応性あり(+)、染色されない場合を反応性なし(-)と判定した。また、中和活性は、実質的に抗ウイルス活性が測定されない場合を中和活性あり(+)、それ以外の場合を中和活性なし(-)と判定した。
<ウエスタンブロッティング分析>
10%(w/v)SDS水溶液0.5ml及びグリセロール1mlからなる混液に実施例1で抗原として使用したrIFNα8或いはnIFNα2を加え、37℃で1時間インキュベートした後、各々の蛋白質量が10又は100ng/レーンとなるようにチャージして、SDS-ポリアクリルアミドゲル電気泳動した。IFN類の蛋白質の分子量に相当する約20乃至29キロダルトン(以下、「KDa」と略記する。)の範囲のゲルに含まれる蛋白質を、常法により、ニトロセルロース膜に移し、非特異的な反応を抑制するためブロッキング溶液(大日本住友製薬社販売、商品名「ブロックエース」)に浸漬した。このブロッキング処理したニトロセルロース膜を、プロテインGセファロースを用いて精製した9種類のモノクローナル抗体のいずれかを2μg/ml含有する溶液に、室温で1時間浸漬した後、0.05%(v/v)ツイーン20を含む50mMトリス-塩酸緩衝液(pH7.5)で洗浄して過剰の抗体を除いた。ニトロセルロース膜を、HRP標識した抗マウスイムノグロブリン又は抗ラットイムノグロブリン(何れもダコ サイトメイション(DAKO Cytomation)社販売)溶液に、室温で1時間浸漬した。この膜を0.05%(v/v)ツイーン20を含む50mMトリス-塩酸緩衝液(pH7.5)で30分間洗浄後、発色反応は、市販のウエスタンブロッティング検出キット(ジーイー ヘルスケア バイオサイエンス社販売、商品名「ECL western blotting detection reagent and Hyperfilm ECL」)を用いて行った。なお、分子量マーカーには、市販のSDS-PAGE用分子量マーカー(バイオラッド社販売、商品名「プレステイン SDS-PAGE スタンダード ブロードレンジ」、構成:ミオシン(204KDa)、β-ガラクトシダーゼ(120KDa)、BSA(100KDa)、オボアルブミン(52KDa)、カーボニックアンヒドラーゼ(37KDa)、ソイビーントリプシンインヒビター(29KDa)、リゾチーム(20KDa)及びアプロチニン(7KDa)を用いた。
実施例4の方法により調製した9種類のモノクローナル抗体を使用して、IFNα8を特異的に定量できるエンザイムイムノアッセイ系の構築に適した抗体のスクリーニングを以下のように行った。
<抗体>
実施例4で調製した9種類のモノクローナル抗体、ウサギポリクローナル抗IFNα抗体(以下、「polyIFNα」と略記する。)及びマウスモノクローナル抗IFNα抗体(以下、「mAbIFNα14」と略記する。)(何れも、株式会社林原生物化学研究所調製)を使用した。なお、polyIFNα及びmAbIFNα14は、IFNα8及びそれ以外のヒトIFNαサブタイプとの反応性を有している。
<ペルオキシダーゼ標識抗体の調製>
常法にしたがって、前記11種類の抗体を、過ヨウ素酸化法によりHRP標識した。すなわち、HRP(ロッシュ(Roche)社販売)10mgを蒸留水2mlに溶解し、0.1M過ヨウ素酸ナトリウム125μlを添加して遮光下、室温で15分間静置した。その後、エチレングリコール100μlを添加後、遮光下で、室温で5分間、1mM酢酸ナトリウム緩衝液(pH4.2)に対し透析した後、HRPが15mg/ml以上になるように濃縮した。この濃縮したHRP8mgと、予め20mg/ml以上に濃縮した前記11種類の抗体のいずれか10mgとを混合し、水を加えて全量を850μlにした後、0.1M炭酸水素ナトリウム緩衝液(pH9.5)150μlを添加して、pHを約9.3に調整して、遮光下、4℃で2時間静置した。その後、4mg/ml水素化ホウ素ナトリウムを100μl添加して、遮光下、室温で、3時間静置後、ゲル濾過用カラム(ジーイー ヘルスケア バイオサイエンス社販売、商品名「Sephacryl S-300HR」)によるゲルろ過にて、HRP標識抗体画分を回収した。回収した画分に、ウシ血清アルブミン(以下、「BSA」と略記する。)を1%となるよう溶解し、膜ろ過(ポアサイズが0.22μm)して、HRP標識抗体(以下、「標識抗体」という。)を調製した。
<エンザイムイムノアッセイの方法>
前記HRP標識した11種類の抗体と、その標識に使用した11種類の未標識の抗体(以下、「未標識抗体」いう。)を固相抗体として使用して、サンドイッチ法による121通りの組み合わせによるエンザイムイムノアッセイで、rIFN蛋白質の定量が可能かどうかを試験した。すなわち、11種類の未標識抗体を、各々抗体濃度が20μg/mlとなるようにPBSで希釈し、その各々をイムノプレートに50μl/ウエル添加して、室温2時間静置後、溶液を除去し、1%BSAを含むPBSを加えて、4℃で一晩、ブロッキング処理をおこなった。ブロッキング後、1%BSAを含むPBSを除去し、rIFNα8を、5%FCS、1%BSA、1M NaClを含むPBSで69pg/ml~60ng/mlに希釈したもののいずれかを、50μl/ウエル添加した。室温で2時間振とう後、各ウエルを、0.05%ツイーン20を含むPBSで3回洗浄した。洗浄に使用したPBSを除去後、前記11種類の標識抗体を、各々5%FCS、1%BSA、0.15M NaCl及び0.1%CHAPSを含むPBSで1μg/mlとなるように希釈して、それぞれを、11種類の未標識抗体を固相に使用したウエルに、50μl/ウエル添加して、室温で2時間振とうした。この標識抗体を含む溶液を除去後、0.05%ツイーン20を含むPBSで3回洗浄後、0.5mg/mlのo-フェニレンジアミン(o-PD)と0.03%H2O2とを含む0.1Mリン酸クエン酸緩衝液(pH5.0)を100μl/ウエル加えて発色させ、2N H2SO4を100μl/ウエル加えて反応を停止して、マルチプレートリーダーで吸光度(OD:A490/650nm)を測定した。対照として、rIFNα8を含まない、5%FCS、1%BSA、1M NaClを含むPBSを加えた場合の吸光度を同様に測定した。なお、測定は1試料につき3ウエルを使用し、その平均を求めた。また、測定した吸光度に基づく検量線の回帰分析による直線性を判定する相関係数(r値)が0.997以上の範囲となるrIFNα8蛋白質の最小濃度と、対照のウエルを測定した時の吸光度(OD)に、その測定値の標準偏差値を3倍した値を加えた値と、rIFNα8蛋白質最小濃度の測定値からその測定値の標準偏差値を3倍した値を減じた値とを比較して、数値の大きい方に相当するrIFNα8蛋白質濃度を、試験したエンザイムイムノアッセイによるrIFNα8蛋白質の検出下限濃度とした。
<IFNα2との交差反応性の確認>
前記エンザイムイムノアッセイの方法において、rIFNα8に換えてrIFNα2を使用した以外は、全く同じ方法で、エンザイムイムノアッセイを行った。rIFNα2の濃度に依存した吸光度の上昇が認められた場合を交差反応あり(「有」)、認められなかった場合を交差反応なし「無」と判定した。
<測定結果>
11種類の未標識抗体(固相)と11種類の標識抗体による121通りの組み合わせのエンザイムイムノアッセイのうち、rIFNα8の濃度に依存した吸光度(OD)の上昇が認められ、且つ、IFNα8を含まない溶液(5%FCS、1%BSA、1M NaCl)の吸光度(OD)が比較的低かった(ODが0.4以下)、14通りの組合せのみを表4に示す。また、表4に示す抗体の組み合わせで、rIFNα8に替えて、IFNα2を使用した場合にrIFNα2の濃度に依存した吸光度(OD)の上昇が認められるかどうか(IFNα2との交差反応の有無)も確認して、その結果を併せて表4に示す。また、上記方法により求めた、14類の組み合わせによるエンザイムアッセイの検出下限濃度(pg/ml)を表4に併せて示す。
実施例5でIFNα8の特異的な検出に使用可能と判断した、固相抗体としてα8#139mAbを使用し、標識抗体としてα8Y36-2mAbを使用するエンザイムイムノアッセイを、後述の方法でおこない、rIFNα8の検量線を作成した結果を図2に示す。また、この検量線に基づき算出した当該エンザイムアッセイ系によるIFNα8蛋白質の検出下限濃度を、実施例5に記載した方法に基づき算出して表5に併せて示す。また、この検量線の直線性を示す相関係数(r値)が0.997以上の範囲の最大のOD値に相当するrIFNα8蛋白質濃度を求めて、当該エンザイムイムノアッセイによるrIFNα8蛋白質の検出上限濃度として表5に併せて示す。
<IFNα8サブタイプ特異的なエンザイムイムノアッセイの特異性の確認>
前記の固相抗体としてα8#139mAbを使用し、標識抗体としてα8Y36-2mAbを使用するエンザイムイムノアッセイ系がIFNα8以外のIFN類やサイトカイン蛋白を検出しないことを確認するために、表5に示す蛋白質濃度のIFN類及びサイトカイン類を当該エンザイムイムノアッセイ系に供したときの吸光度の測定結果を表5に併せて示す。
<エンザイムイムノアッセイの方法>
固相抗体としてα8#139mAbを、20μg/mlにPBSで希釈して、イムノプレート(NUNC社販売)に100μl/ウエルで分注した。室温で3時間静置後、固相溶液を捨て、1%BSAを含むPBSを250μl/ウエル加えて、4℃で一晩静置してブロッキングを行った。1%BSAを含むPBSを除去後、標準品として、2.5%FCS、0.5%BSA及び0.5M NaClを含むPBSで、rIFNα8を10乃至2,000pg/mlに希釈した溶液を調製した。また、表5に示すIFN類又はサイトカイン類を被験試料として、rIFNα8の希釈に使用したものと同じFCS、BSA及びNaClを含むPBSで10ng/mlに希釈した溶液のいずれかを、100μl/ウエル添加して室温で、3時間振とうした。その後、標準品溶液或いは被験試料を含む溶液を除去後、0.05%ツイーン20含有PBSで3回洗浄した。洗浄液を除去後、5%FCS、1%BSA、0.15M NaCl及び0.1%CHAPSを含むPBSで1μg/mlに希釈したHRP標識したα8Y36-2mAbを、100μl/ウエル添加して、室温2時間振とう後、0.05%ツイーン20を含むPBSで3回洗浄した。洗浄液を除去後、0.5mg/mlのo-PDと0.03%H2O2を含有する0.1Mリン酸クエン酸緩衝液(pH5.0)を100μl/ウエル添加して発色させた後、2N H2SO4を100μl/ウエル添加して発色反応を停止させて、マルチプレートリーダーで吸光度(OD:A490/650nm)を測定した。なお、測定は1試料につき3ウエルを使用し、その平均を求めた。
常法にしたがって、実施例4の方法により得たα8#139mAbを常法によりラジオイムノアッセイ用ポリスチレンビーズに吸着させ、2%(w/v)BSAを含むPBS中、4℃で一晩静置して固相抗体ビーズを調製した。
ヒトリンパ芽球様細胞株のBALL-1細胞(株式会社林原生物化学研究所所有)にHVJを加えて誘導されたnIFNαは、nIFNα2とnIFNα8(IFNα8b)とを、72±9:28±9の比率(質量)で含有し、nIFNα7をわずかに含むことが知られている(例えば、シゲハル フクダ等(Shigeharu Fukuda et al.)、『リンフォカイン(Lymphokine)』、第7巻、第2号、第175乃至185頁(1988年)参照)。実施例6で使用した本発明のエンザイムイムノアッセイ系が、このBALL-1細胞由来のヒトnIFNα中のnIFNα8を特異的に定量できることを確認するために以下の試験を行った。すなわち、BALL-1細胞をハムスターの新生仔の背部皮下に移植し、増殖させたBALL-1細胞を、RPMI1640培地に浮遊させて、HVJを加えて一晩培養した培養上清に紫外線を照射してHVJを不活化した溶液(以下、「BALL―1培養上清」と略記する。)、及び、当該溶液をモノクローナル抗体カラム(ロンザ社販売、商品名「NK2-セファロース」)で精製したヒトnIFNα標品を、バイオアッセイ、及び、IFNα2又はIFNα8特異的なエンザイムイムノアッセイに供した。その結果を表6に示す。また、バイオアッセイでは、予め、実施例4で調製した抗IFNα8抗体(α8#139mAb)を加えてnIFNα8の活性を特異的に中和した標品の活性を測定した結果も併せて表6に示す。なお、エンザイムイムノアッセイには、nIFNα8の定量は、実施例6で構築したアッセイ系を使用し、nIFNα2は市販のIFNαアッセイキット(株式会社JIMRO販売、商品名「ヒトIFN-α測定キット」)を使用した。また、測定は1試料につき3ウエルを使用し、その平均を求めた。
ヒトnIFNα(nIFNα2を6.46μg、nIFNα8を1.81μg含有)、実施例6で使用したIFNα8-MUT2(5.83μg含有)又はIFNα8-MUT3(5.38μg含有)を、各々4匹のBALB/cマウス(株式会社日本チャールスリバー販売、メス、9週齢)に、約106IU/匹で皮下投与した。投与後、経時的(0、0.5、1、2、3、6、24時間)に尾静脈から血液をサンプリングし、遠心後得られた血漿を、実施例8で使用したものと同じIFNα2、IFNα8特異的なエンザイムイムノアッセイに供した。測定結果に基づき、IFNα8又はその変異蛋白質を投与したときの各マウスにおけるAUC(血中濃度-時間曲線下面積)、MRT(平均滞留時間)、Cmax(最高血中濃度)、Tmax(最高血中濃度到達時間)及びEBA(生物学的利用率)を求め、各IFN標品を投与した4匹のマウスの平均を求めて表7に示す。なお、測定は1試料につき3ウエルを使用し、その平均を求めた。
実施例4の方法により得たα8#139mAbの精製品を80mgとり、0.5M塩化ナトリウムを含む0.1M硼酸緩衝液(pH8.5)に対して4℃で一晩透析した。水不溶性担体(ジーイー ヘルスケア バイオサイエンス社販売、商品名「CNBr-活性化セファロース4B」)4gを1mM塩酸水溶液中で膨潤させ、新鮮な1mM塩酸水溶液、0.5M塩化ナトリウムを含む0.1M硼酸緩衝液(pH8.5)の順序で洗浄した後、上記のモノクローナル抗体水溶液約10mlを加え、室温下で2時間、4℃でさらに一晩緩やかに攪拌した。その後、ゲルを1Mエタノールアミン水溶液(pH8.0)で洗浄し、さらに、0.5M塩化ナトリウムを含む0.1M硼酸緩衝液(pH8.5)及び0.5M塩化ナトリウムを含む0.1M酢酸緩衝液(pH4.0)をこの順序で用いて洗浄する工程を5回繰返し、最後にPBSで洗浄してイムノアフィニティークロマトグラフィー用ゲルを得た。常法により分析したところ、ゲル1ml当たり、約6mgのモノクローナル抗体α8#139mAbが結合していた。
実施例10で得たイムノアフィニティークロマトグラフィー用ゲル10mlをプラスチック製円筒管内部にカラム状に充填し、PBSで洗浄後、特許第112301号公報に記載された方法により、免疫抑制したハムスターに移植して増殖させたBALL-1細胞に、HVJを加えて産生させたヒトnIFNαを約0.1mg/ml含む画分40mlを負荷した。新鮮なPBSで洗浄した後、カラムに、0.3MのNaClを含む0.1Mクエン酸緩衝液(pH1.9)を通液し、抗ウイルス活性のある画分を採取した。採取した画分をプールし、濃縮後、蛋白質含量を測定したところ、純度99.8%以上の精製蛋白質が得られたことが判明した。また、この精製蛋白質を、実施例8で使用したIFNα2或いはIFNα8特異的なエンザイムイムノアッセイに供したところ、IFNα2蛋白質は検出されず、IFNα8のみが検出された。その蛋白質量は、nIFNα8の比活性を勘案すると、当該精製蛋白質の抗ウイルス活性とよく一致しており、また、カラムに負荷したヒトnIFNαに含まれているnIFNα8のほぼ全量が回収されていたので、当該抗体カラムがIFNα8精製用に好適なことが判明した。
ハイブリドーマα8#139(独立行政法人産業技術総合研究所 特許生物寄託センター、受託番号FERM BP-11081)の産生するモノクローナル抗体α8#139mAbの重鎖及び軽鎖可変部を含む領域のcDNA断片のクローニングと塩基配列(アミノ酸配列を含む)の同定を以下のようにおこなった。
α8#139を常法により培養して、約3×106個の細胞を調製した。市販のRNA調製キット(QIAGEN社販売、商品名「RNeasy Mini Kit(Cat.No.74104)」)
を用いてその取扱説明書中の「遠心法を用いた動物細胞からのトータルRNA精製」に従って、細胞のホモジネートからRNAを抽出して、30乃至60μgのRNAを得た。なお、細胞のホモジネートの調製には、市販のカラム(QIAGEN社販売、商品名「QIAshredder Spin Column」)を使用し、その際DNAaseI処理は行わなかった。
逆転写酵素反応及びPCR反応は、市販のキットを使用した(Invitrogen社販売、商品名「SuperScript III逆転写酵素(カタログ番号18080-044)」)を用いて、その取扱説明書「First Strand cDNA Synthesis」に従って、市販のoligo(dT)12-18(Invitrogen社販売、カタログ番号18418-012)をプライマーとして逆転写酵素反応を実施した。得られたcDNAを鋳型として、市販のMouse Ig-Primerセット(Novagen社販売、カタログ番号#69831-3)をプライマーとして、PCR反応を行った。DNAポリメラーゼは、市販品(TOYOBO社販売、商品名「KOD-Plus-(カタログ番号KOD-201)」、以下、「KODキット)という)を使用した。また、このKODキットで増幅ができなかった場合には、タカラバイオ社販売、商品名「TaKaRa Ex Taq(code RR001A)」、以下、「Ex Taqキット」という。)を使用した。なお、Mouse Ig-Primerセットのうち、α8#139mAbの重鎖可変部領域のDNA増幅には、5’プライマーとして6本のプライマー「MuIgGVH5’A~F」と、3’プライマーとして1本のプライマー「MuIgGVH3’-2」を用いた組み合わせでPCRを行った。α8#139mAbの軽鎖可変部領域の増幅には、5’プライマーとして7本のプライマー「MuIgκVH5’A~G」と3’プライマーとして1本のプライマー「MuIgκVL3’-1」を使用した。なお、5‘プライマーは何れも、開始コドンを含む塩基配列含むものを使用した。以下に、KODキットとEx Taqキット使用時の反応条件を示す。
KOD-Plus-(1U/μl) 0.5μl
10×PCR Buffer 2.5μl
25mM MgSO4 1μl
2mM dNTPs 2.5μl
逆転写酵素反応後鋳型 1μl
5’プライマー:
5’A and B プライマーの場合 12.5pmol
或いは、
5’C-G プライマーの場合 5pmol
3’プライマー 2.5pmol
適量の蒸留水を加えて全量を25μl/チューブとする。
このチューブを、94℃ 2分処理後、94℃、15秒、処理温度*、30秒、68℃ 1分の3つの温度サイクルで、30乃至40回繰り返し処理し、4℃に冷却する。
処理温度*;5’A and B Leaderプライマーは50℃、5’C-G Leaderプライマーは60℃で行った。
<Ex Taqキットの反応条件>
Ex Taq(5U/μl) 0.25μl
10×Ex Taq PCR Buffer 5μl
2.5mM dNTPs 4μl
逆転写酵素反応後鋳型 1μl
5’プライマー:
5’A and B プライマーの場合 25pmol
或いは、
5’C-G プライマーの場合 10pmol
3’プライマー 5pmol
適量の蒸留水を加えて全量を50μl/チューブとする。
このチューブを、94℃、1分、処理温度*、1分、72℃、1分の3つの温度サイクルで、30乃至35回繰り返し処理し、4℃に冷却する。
処理温度*;5’A and B Leaderプライマーsは50℃、5’C-G Leaderプライマーは60℃で行った。
上記の重鎖及び軽鎖可変部領域のDNAを増幅したPCR反応液を、各々アガロースゲル電気泳動に供し、約500bpのDNA増幅断片を含むゲルから、市販のキット(QIAGEN 社販売、商品名「QIAEX II Gel Extraction Kit」)を使用して、その取扱説明書の「QIAEX II Agarose Gel Extraction Protocol」、或いは、市販のキット(Stratagene社販売、商品名「PCR-Script Cam Cloning Kit(#211192)」に含まれる「StrataPrep PCR Purification Kit」)を使用して、その取扱説明書の「Purifying the PCR Products with the StrataPrep PCR Purification Kit」に従って、PCR後の反応液からPCR増幅断片を精製した。また、Ex Taqキットで増幅したDNA断片は、Stratagene社のPCR-Script Cam Cloning Kitの操作方法「Polishing the Purified PCR Products」に従ってDNA断片の末端の平滑化を行った。
得られた精製DNA断片は、Stratagene社のPCR-Script Cam Cloning Kit(#211192) を用いて pPCR-Script Cam SK(+)Vectorにライゲートし、同キットのコンピテントセルXL10-Goldをトランスフォームした。続いてX-gal、クロラムフェニコール、IPTG含有プレートに播種後、白いコロニーをピックアップし、コロニーダイレクトPCR法により、目的とするサイズのインサートを含むクローンを選択した。目的とするサイズの断片を含むコロニーの培養液から、市販のプラスミド調製キット(QIAGEN社販売、商品名「QIAprep spin Miniprep Kit(Cat No.27106)」)を用いてプラスミドを調製した。以下に、コロニーダイレクトPCR法の反応条件を示す。
Ex Taq(5U/μl) 0.05μl
10×Ex Taq PCR Buffer 1μl
2.5mM dNTPs 0.8μl
T3 プライマー 10ng
T7 プライマー 10ng
蒸留水を加えて全量を10μl/チューブとする。
チップでついたコロニーのレプリカをとり、チューブの反応液に混ぜる。
このチューブを、94℃、1分、55℃、1分、72℃、1分の3つ温度サイクルで、30乃至35回繰り返し処理し、4℃に冷却する。
<シークエンス>
DNAの塩基配列は、DNA自動シークエンサー(BECKMAN COULTER社販売、商品名「CEQ8000」)を用い、ベクターのT3プライマー(5’AATTAACCCTCACTAAAGGG3’:配列表における配列番号1)、T7プライマー(5’GTAATACGACTCACTATAGGGC3’:配列表における配列番号2)を用いて双方向よりシーケンシング反応を行い、重鎖可変部領域をコードするDNAを含むクローン3個及び軽鎖可変部領域をコードするDNAを含むクローン3個を得て、そのDNAの塩基配列を決定した。重鎖可変部領域をコードするDNAを含むクローン3個のうちの2個のクローンは配列表における配列番号3で示される塩基配列を、残りの1クローンは配列表における配列番号4で示される塩基配列を有していた。また、軽鎖可変部領域の配列を含む3個のクローンは、いずれも配列表における配列番号5で示される塩基配列を有していた。
上記3個のDNAの塩基配列に基づき、クローニングに使用した5’プライマー部分のアミノ酸配列に続く、α8#139mAbの重鎖及び軽鎖の可変部領域を含むアミノ酸配列を推定した結果を、各々、配列表における配列番号6乃至8で示されるアミノ酸配列に示す。また、既知の重鎖及び軽鎖の不変領域のアミノ末端のアミノ酸配列に基づき、重鎖及び軽鎖のカルボキシ末端のアミノ酸を決定し、α8#139mAbの重鎖及び軽鎖の可変部領域のアミノ酸配列を決定して、各々配列表における配列番号9乃至11で示されるアミノ酸配列に示す。配列表における配列番号10で示されるアミノ酸配列は、配列表における配列番号9で示されるアミノ酸配列のうちの、アミノ末端から37番目のフェニルアラニン(Phe)がイソロイシン(Ile)で、79番目のイソロイシン(Ile)がスレオニン(Thr)で置換された配列を有していた。得られたクローンの数からすると、α8#139mAbの重鎖可変部位のアミノ酸配列は、配列表における配列番号9で示されるアミノ酸配列を有し、一部の抗体は、配列表における配列番号10で示されるアミノ酸配列を有していることを物語っている。
ハイブリドーマα8Y36-2(独立行政法人産業技術総合研究所 特許生物寄託センター、受託番号FERM BP-11082)の産生するモノクローナル抗体α8Y36-2mAbの重鎖及び軽鎖可変部領域のcDNA断片のクローニングと塩基配列(アミノ酸配列を含む)の同定を、以下のようにおこなった。即ち、α8Y36-2を常法により培養して、約3×106個の細胞を調製した。RNAの抽出以降の操作は、実施例12と同一の方法で行った。重鎖の可変部領域をコードするDNAを含むクローン3個及び軽鎖可変部領域をコードするDNAを含むクローン2個を得て、そのDNAの塩基配列を決定した。重鎖の可変部領域をコードするDNAを含むクローン3個のうちの2クローンは配列表における配列番号12で示される塩基配列を、残りの1クローンは配列表における配列番号13で示される塩基配列を有していた。また、軽鎖可変部領域の配列を含む2個のクローンは、いずれも配列表における配列番号14で示される塩基配列を有していた。
上記3個のDNAの塩基配列に基づき、クローニングに使用した5’プライマー部分のアミノ酸配列に続く、α8Y36-2mAbの重鎖及び軽鎖の可変部領域を含むアミノ酸配列を推定した結果を、各々、配列表における配列番号15乃至17で示されるアミノ酸配列に示す。また、既知の重鎖及び軽鎖の不変領域のアミノ末端のアミノ酸配列に基づき、重鎖及び軽鎖のカルボキシ末端のアミノ酸を決定し、α8Y36-2mAbの重鎖及び軽鎖の可変部領域のアミノ酸配列を決定して、各々配列表における配列番号18乃至20で示されるアミノ酸配列に示す。配列表における配列番号19で示されるアミノ酸配列は、配列表における配列番号18で示されるアミノ酸配列のうちの、アミノ末端から19番目のグリシン(Gly)がアスパラギン酸(Asp)で置換された配列を有していた。得られたクローンの数からすると、α8Y36-2mAbの重鎖可変部位のアミノ酸配列は、配列表における配列番号18で示されるアミノ酸配列を有し、一部の抗体は、配列表における配列番号19で示されるアミノ酸配列を有していることを物語っている。
実施例4の方法により調製した9種類のモノクローナル抗体のいずれかを150mg/ml、α,α-トレハロース(株式会社林原生物化学研究所製造、パイロジェンフリー)を140mg/ml、L-塩酸ヒスチジンを3.4mg/ml、L-ヒスチジンを2.2mg/ml、及び、ツイーン20を0.6mg/mlとなるように精製水に溶解して、1mlずつバイアル瓶に分注し、常法により、9種類の注射用の凍結乾燥製剤を調製した。本品は、使用時に生理食塩水に溶解して注射剤とし使用することができる。本品は、IFNα8が発症や増悪に関与する各種疾患の治療剤として有用である。これら9種類の乾燥製剤を、各々生理食塩水で溶解し、各製剤を、各々5匹のラット(平均体重123g/匹)に、1日1回、7日間毎日、5ml/匹(モノクローナル抗体として750mg/匹/回)腹腔内投与して、体重を毎日測定した。対照として、5匹のラット(平均体重127g/匹)に、1日1回、7日間毎日、生理食塩水を5ml/匹腹腔内投与して、体重を毎日測定した。各製剤を投与したラットの体重と対照のラットの体重とを比較したところ、何れの製剤を投与した場合にも、対照と差は認められなかった。また、外観的な観察でも、各製剤を投与したラット及び対照のラットに、何ら異常は認められなかった。
実施例12で得たα8#139mAbの重鎖及び軽鎖の可変部位を含む領域をコードする塩基配列(配列表における配列番号3乃至5)及び可変部位のアミノ酸配列(配列表における配列番号9乃至11)に基づき、常法によりヒト化抗体を調製して、純度99.98%以上に精製後、その抗体を200mg/ml、α,α-トレハロース(株式会社林原生物化学研究所製造、パイロジェンフリー)を140mg/ml、L-塩酸ヒスチジンを3.4mg/ml、L-ヒスチジンを2.2mg/ml、及び、ツイーン20を0.6mg/mlとなるように精製水に溶解して、1mlずつバイアル瓶に分注し、常法により、凍結乾燥製剤を調製した。本品は、使用時に生理食塩水に溶解して注射剤とし使用することができる。本品は、IFNα8が発症や増悪に関与する各種疾患の治療剤として有用である。本品を生理食塩水で溶解して、5匹のマウス(平均体重23g/匹)に、1日1回、7日間毎日、0.5ml/匹(モノクローナル抗体として100mg/匹/回)静脈内投与して、体重を毎日測定した。対照として、5匹のマウス(平均体重24g/匹)に、1日1回、7日間毎日、生理食塩水を0.5ml/匹静脈内投与して、体重を毎日測定した。本品を投与したマウスと対照のマウスの体重を比較したところ、差は認められなかった。また、外観的な観察でも、本品を投与したマウス及び対照のマウスに、何ら異常は認められなかった。
実施例13で得たα8Y36-2mAbの重鎖及び軽鎖の可変部位を含む領域をコードする塩基配列(配列表における配列番号12乃至14)及びそのアミノ酸配列(配列表における配列番号18乃至20)に基づき、常法によりヒト化抗体を調製して、純度99.98%以上に精製後、その抗体を200mg/ml、α,α-トレハロース(株式会社林原生物化学研究所製造、パイロジェンフリー)を140mg/ml、L-塩酸ヒスチジンを3.4mg/ml、L-ヒスチジンを2.2mg/ml、及び、ツイーン20を0.6mg/mlとなるように精製水に溶解して、1mlずつバイアル瓶に分注し、常法により、凍結乾燥製剤を調製した。本品は、使用時に生理食塩水に溶解して注射剤とし使用することができる。本品は、IFNα8が発症や増悪に関与する各種疾患の治療剤として有用である。本品を生理食塩水で溶解して、5匹のマウス(平均体重23g/匹)に、1日1回、7日間毎日、0.5ml/匹(モノクローナル抗体として100mg/匹/回)静脈内投与して、体重を毎日測定した。対照として、5匹のマウス(平均体重23g/匹)に、1日1回、7日間毎日、生理食塩水を0.5ml/匹静脈内投与して、体重を毎日測定した。本品を投与したマウスと対照のマウスの体重を比較したところ、差は認められなかった。また、外観的な観察でも、本品を投与したマウス及び対照のマウスに、何ら異常は認められなかった。
Claims (14)
- 抗ヒトインターフェロン(IFN)αモノクローナル抗体であって、ヒトIFNαサブタイプα8(IFNα8)及びその変異蛋白質との結合能を有し、ヒトIFNαサブタイプα1、α2、α5、α6、α10、コンセンサスIFN、ヒトIFNβ、ヒトIFNγ、マウスIFNα/β、ラットIFNα及びヒト腫瘍壊死因子(TNFα)と実質的に結合しない単離されたモノクローナル抗体。
- ヒトIFNα8及びその変異蛋白質の定量に使用する請求の範囲第1項記載のモノクローナル抗体。
- ヒトIFNα8及びその変異蛋白質の精製に使用する請求の範囲第1項記載のモノクローナル抗体。
- ヒトIFNα8の変異蛋白質が、ヒトIFNαサブタイプα8bのアミノ酸配列のアミノ末端のシステイン残基から145番目のアルギニン残基をイソロイシン残基又はロイシン残基に、146番目のアラニン残基をセリン残基に、149番目のメチオニン残基をチロシン残基に置換したアミノ酸配列を有する請求の範囲第1項乃至第3項のいずれかに記載のモノクローナル抗体。
- 重鎖可変領域に配列表における配列番号21、22、23、27、28及び29で示されるアミノ酸配列のいずれかのアミノ酸配列を含む請求の範囲第1項乃至第4項のいずれかに記載のモノクローナル抗体。
- 軽鎖可変領域に配列表における配列番号24、25、26、30、31又は32で示されるアミノ酸配列のいずれかのアミノ酸配列を含む請求の範囲第1項乃至第5項のいずれかに記載のモノクローナル抗体。
- 重鎖可変領域に配列表における配列番号9、10、18及び19で示されるアミノ酸配列のいずれかのアミノ酸配列を含む請求の範囲第1項乃至第6項のいずれかに記載のモノクローナル抗体。
- 軽鎖可変領域に配列表における配列番号11又は20で示されるアミノ酸配列を含む請求の範囲第1項乃至第7項のいずれかに記載のモノクローナル抗体。
- ハイブリドーマmAb-IFNα8#139(独立行政法人産業技術総合研究所 特許生物寄託センター、受託番号FERM BP-11081)又はmAb-IFNα8Y36-2(独立行政法人産業技術総合研究所 特許生物寄託センター、受託番号FERM BP-11082)が産生するモノクローナル抗体か、該モノクローナル抗体の抗原結合部位と相同の結合部位を有する請求の範囲第1項乃至第8項のいずれかに記載のモノクローナル抗体。
- ヒトIFNα8及びその変異蛋白質の抗ウイルス活性に対する中和能を有する請求の範囲第1項乃至第9項のいずれかに記載のモノクローナル抗体。
- ヒトIFNα8及びその変異蛋白質に特異的な定量方法であって、請求の範囲第1項乃至第10項のいずれかに記載のモノクローナル抗体から選ばれるいずれか1種又は2種を用いる定量方法。
- ヒトIFNα8及びその変異蛋白質に特異的な精製方法であって、請求の範囲第1項乃至第10項のいずれかに記載のモノクローナル抗体から選ばれるいずれかを担体に固定化した抗体カラムを使用する工程を含む精製方法。
- 請求の範囲第1項乃至第10項のいずれかに記載のモノクローナル抗体を産生するハイブリドーマ。
- 請求の範囲第1項乃至第10項のいずれかに記載のモノクローナル抗体又はその抗原認識部位を有する断片を含む医薬組成物又は臨床診断薬。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09723517A EP2272872A4 (en) | 2008-03-21 | 2009-03-16 | MONOCLONAL ANTIBODIES SPECIFICALLY RECOGNIZING THE ALPHA 8 SUBTYPE OF THE HUMAN ALPHA INTERFERON AND ASSOCIATED MUTANT PROTEIN |
JP2010503863A JPWO2009116491A1 (ja) | 2008-03-21 | 2009-03-16 | ヒトインターフェロンαサブタイプα8及びその変異蛋白質を特異的に認識するモノクローナル抗体 |
US12/933,768 US8357782B2 (en) | 2008-03-21 | 2009-03-16 | Monoclonal antibodies specific for human interferon-alpha subtype alpha 8 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008-072729 | 2008-03-21 | ||
JP2008072729 | 2008-03-21 | ||
JP2008149916 | 2008-06-06 | ||
JP2008-149916 | 2008-06-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2009116491A1 true WO2009116491A1 (ja) | 2009-09-24 |
Family
ID=41090893
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2009/055039 WO2009116491A1 (ja) | 2008-03-21 | 2009-03-16 | ヒトインターフェロンαサブタイプα8及びその変異蛋白質を特異的に認識するモノクローナル抗体 |
Country Status (5)
Country | Link |
---|---|
US (1) | US8357782B2 (ja) |
EP (1) | EP2272872A4 (ja) |
JP (1) | JPWO2009116491A1 (ja) |
KR (1) | KR20110005806A (ja) |
WO (1) | WO2009116491A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2981662C (en) | 2011-01-14 | 2019-02-05 | The Regents Of The University Of California | Therapeutic antibodies against ror-1 protein and methods for use of same |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6412301A (en) | 1987-07-07 | 1989-01-17 | Olympus Optical Co | Servo circuit |
JPH0611235B2 (ja) | 1980-04-11 | 1994-02-16 | セルテック・リミテッド | モノクロ−ナル抗体 |
JPH09509955A (ja) | 1994-03-07 | 1997-10-07 | インペリアル カレッジ オブ サイエンス,テクノロジー アンド メディシン | ウィルス感染を治療する薬剤の調製におけるインターフェロンのサブタイプの使用 |
EP0915099A1 (en) * | 1997-11-04 | 1999-05-12 | ALFA WASSERMANN S.p.A. | Antiparallel oligopeptides and hydrophobically complementary oligopeptides, matrices containing them and use thereof in the purification and detection of subtypes of alpha interferon |
JP2004533217A (ja) | 2001-02-22 | 2004-11-04 | ジェネンテック・インコーポレーテッド | 抗インターフェロンα抗体 |
WO2006051805A1 (ja) | 2004-11-12 | 2006-05-18 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | インターフェロンα変異蛋白質とその用途 |
JP2007063177A (ja) | 2005-08-31 | 2007-03-15 | Hayashibara Biochem Lab Inc | 美肌用の経口摂取用組成物 |
JP2007252372A (ja) | 2006-02-23 | 2007-10-04 | Mitsubishi Pharma Corp | モノクローナル抗体およびそれをコードする遺伝子、ハイブリドーマ、医薬組成物ならびに診断試薬 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101225299B1 (ko) * | 2003-12-10 | 2013-01-24 | 메다렉스, 인코포레이티드 | 인터페론 알파 항체 및 그의 용도 |
-
2009
- 2009-03-16 WO PCT/JP2009/055039 patent/WO2009116491A1/ja active Application Filing
- 2009-03-16 JP JP2010503863A patent/JPWO2009116491A1/ja active Pending
- 2009-03-16 EP EP09723517A patent/EP2272872A4/en not_active Withdrawn
- 2009-03-16 US US12/933,768 patent/US8357782B2/en not_active Expired - Fee Related
- 2009-03-16 KR KR1020107022757A patent/KR20110005806A/ko not_active Application Discontinuation
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0611235B2 (ja) | 1980-04-11 | 1994-02-16 | セルテック・リミテッド | モノクロ−ナル抗体 |
JPS6412301A (en) | 1987-07-07 | 1989-01-17 | Olympus Optical Co | Servo circuit |
JPH09509955A (ja) | 1994-03-07 | 1997-10-07 | インペリアル カレッジ オブ サイエンス,テクノロジー アンド メディシン | ウィルス感染を治療する薬剤の調製におけるインターフェロンのサブタイプの使用 |
EP0915099A1 (en) * | 1997-11-04 | 1999-05-12 | ALFA WASSERMANN S.p.A. | Antiparallel oligopeptides and hydrophobically complementary oligopeptides, matrices containing them and use thereof in the purification and detection of subtypes of alpha interferon |
JP2004533217A (ja) | 2001-02-22 | 2004-11-04 | ジェネンテック・インコーポレーテッド | 抗インターフェロンα抗体 |
WO2006051805A1 (ja) | 2004-11-12 | 2006-05-18 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | インターフェロンα変異蛋白質とその用途 |
JP2007063177A (ja) | 2005-08-31 | 2007-03-15 | Hayashibara Biochem Lab Inc | 美肌用の経口摂取用組成物 |
JP2007252372A (ja) | 2006-02-23 | 2007-10-04 | Mitsubishi Pharma Corp | モノクローナル抗体およびそれをコードする遺伝子、ハイブリドーマ、医薬組成物ならびに診断試薬 |
Non-Patent Citations (9)
Title |
---|
EIJI ISHIKAWA: "Enzyme Immunoassay", 1989, TOKYO-KAGAKU-DOJIN, pages: 196 - 348 |
MOLECULAR IMMUNOLOGY, vol. 29, no. 3, 1992, pages 391 - 399 |
SAKUJI TOYAMA; TAMIE ANDO: "Tan-Clone-Kotai-Jikken-Manual", 1991, KODANSHA SCIENTIFIC, LTD., pages: 105 - 152 |
SATO M. ET AL.: "Hito Jin Saibo Gan Saibo ni Taisuru Interferon a subtype ni yoru Koshuyo Koka no Chigai", 94TH JAPANESE JOURNAL OF UROLOGY, vol. 97, no. 2, 2006, pages 417, XP008144142 * |
See also references of EP2272872A4 * |
SHIGEHARU FUKUDA ET AL., LYMPHOKINE, vol. 7, no. 2, 1988, pages 175 - 185 |
USHIO, C. ET AL.: "Establishment of Antihuman IFN- alpha8-Specific Monoclonal Antibodies and Their Application in the Enzyme-Linked Immunosorbent Assay(ELISA).", J.INTERFERON CYTOKINE RES., vol. 28, no. 6, June 2008 (2008-06-01), pages 359 - 366, XP008144146 * |
VANCOVA,I. ET AL.: "The Carboxyterminal Domains of Human IFN-a2 and IFN-a8 Are Antigenically Homologous.", J.INTERFERON CYTOKINE RES., vol. 20, no. 5, 2000, pages 455 - 461, XP009001290 * |
YANAI Y. ET AL., JOURNAL OF INTERFERON & CYTOKINE RESEARCH, vol. 21, no. 10, 2001, pages 835 - 841 |
Also Published As
Publication number | Publication date |
---|---|
KR20110005806A (ko) | 2011-01-19 |
EP2272872A4 (en) | 2011-04-06 |
JPWO2009116491A1 (ja) | 2011-07-21 |
US20110091968A1 (en) | 2011-04-21 |
EP2272872A1 (en) | 2011-01-12 |
US8357782B2 (en) | 2013-01-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111690058B (zh) | 针对冠状病毒的具有中和活性的抗体及其用途 | |
JP6740308B2 (ja) | 骨髄細胞で発現されるトリガー受容体1(trem−1)に結合し、それを遮断する抗体 | |
CN112250763B (zh) | 靶向SARS-CoV-2冠状病毒的抗体及其诊断和检测用途 | |
JP6400480B2 (ja) | ペプチドグリカン認識タンパク質1に結合する抗体 | |
CN111718414B (zh) | 抗人白介素23单克隆抗体及其应用 | |
JP6081699B2 (ja) | Il−28bの分析方法 | |
CN107108733B (zh) | 抗活性型gip抗体 | |
CN114621345A (zh) | 一种抗lag-3的单克隆抗体、其抗原结合片段及其应用 | |
JP2016531090A (ja) | ヒト抗ifn−アルファ抗体 | |
CN115298216A (zh) | 抗体或其抗原结合片段、其制备方法及医药用途 | |
WO2009116491A1 (ja) | ヒトインターフェロンαサブタイプα8及びその変異蛋白質を特異的に認識するモノクローナル抗体 | |
JP5821198B2 (ja) | 抗il28b抗体及びこれを用いたil28bの測定方法 | |
JP4059404B2 (ja) | 甲状腺機能を刺激する活性を持つ抗体 | |
CN111892657A (zh) | 用于检测米田堡血型抗原的抗体及其片段、试剂盒及方法 | |
EP2187216B1 (en) | Novel liver cancer marker | |
CN116063536B (zh) | 抗人MxA单克隆抗体及其制备方法和应用 | |
US20090176238A1 (en) | Cynomolgus Toll-Like Receptor 3 | |
CN114716547B (zh) | 一种包括抗原结合结构域的结合蛋白及其生产方法和应用 | |
CN112979798B (zh) | 一种包含c反应蛋白抗原结合结构域的分离的结合蛋白 | |
CN112979803B (zh) | 特异性结合pct的结合蛋白、其应用、诊断感染性炎症的试剂和试剂盒 | |
WO2019194217A1 (ja) | 検出感度の高いインターロイキン-18タンパク質に対する抗体及びその応用 | |
CN113999306A (zh) | 一种获得识别空间构象表位抗体的方法 | |
JP2011160696A (ja) | 修飾ヒトigf−1/eペプチドに対する抗体 | |
JP2023535233A (ja) | グリコシル化ceacam5に特異的に結合した抗体 | |
CN115057935A (zh) | 抗人弹性蛋白酶抑制蛋白抗体、试剂盒及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09723517 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010503863 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12933768 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20107022757 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009723517 Country of ref document: EP |